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Manufacturing licences in place 
at year end – 127 for human 
medicines and 23 for veterinary 
medicines
150
International Conference of Drug 
Regulatory Authorities (ICDRA) 
hosted in Dublin by the HPRA in 
collaboration with the WHO 
18th
The number of Reference 
Member State (RMS) transfers to 
Ireland for human and veterinary 
medicines in advance of Brexit
502
Public sector organisation 
to receive the Keepwell 
Mark Workplace Wellbeing 
accreditation 
1st
The total approximate number 
of veterinary medicines now 
authorised for the Irish market – 
a record high figure
1,800
Applications issued for clinical 
trials of human medicines 
100
Applications for new clinical 
investigations of medical devices 
9 
The total number of new human 
medicines authorised during 2018
376
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2018 Statistics 
at a Glance 
  
Export certificates issued – 
1,428 certificates for medicines 
and 2,581 free sale certificates 
for medical devices
4,009 
GMP inspections conducted at 
manufacturing sites for human 
and veterinary medicines, and 
active substances 
116
EU PSUR single assessment 
procedures for human medicines 
led by the HPRA
28
Medical device vigilance reports 
received and assessed
Reactive surveillance cases 
initiated for cosmetic products
Unique visitors to our 
website – our highest ever 
annual figure
2,358
379
500,000+ 
Market surveillance cases 
undertaken in respect of medical 
devices
Dosage units of fake (falsified) 
and other illegal medicines 
detained
1,604
619,213 
Medicine recalls consisting  
of 196 human medicines and  
6 veterinary medicines
202
Reports of suspected adverse 
reactions associated with use of 
veterinary medicines
394 
Suspected adverse reaction 
reports for human medicines 
received
10,398
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Chairperson’s 
Statement
As I present the 2018 Annual Report,  
now in my fourth year as Chair, I continue  
to be incredibly proud of my association 
with the Health Products Regulatory 
Authority (HPRA). 
The HPRA’s five-year Strategic Plan (2016-2020), 
which sets the direction for the agency, reached its 
mid-way point in 2018. The Authority invested time in 
the midterm review of the plan and began discussions 
on proposals for the next iteration of the Strategic 
Plan, for which development will begin in 2019. As 
an Authority, we are very much looking forward to 
working with the management team and staff to set 
the future direction, with input from our stakeholders 
and key health sector representatives. 
HPRA Strategic Goals 2016-2020
The primary focus and work of the HPRA in 2018, as 
in previous years, was the protection of public and 
animal health and Dr Lorraine Nolan, Chief Executive, 
elaborates on this in her report. 
I would like to highlight and acknowledge the early 
action and cohesive, strategic approach taken by the 
agency in response to the UK’s decision to leave the 
EU. The work at national and EU level has been stellar 
and relentless. I and my fellow Authority members 
are invested in the steps taken to develop the HPRA’s 
strategic response to this issue to ensure the best 
possible outcome is achieved for the protection of 
public and animal health in Ireland.
The composition of the Authority changed in 2018, 
with the retirement of Professor Mary Horgan. 
Professor Horgan was also Chair of the Advisory 
Committee on Human Medicines and contributed 
greatly to the organisation since 2003. Her 
professional approach and technical acumen was 
valued by colleagues across the organisation. In 
2018, in light of upcoming changes to the Authority, 
I progressed an initiative in respect of succession 
planning and am pleased to say we have developed 
a robust framework which will ensure the skills, 
competencies and technical requirements will be met 
by the Authority of the HPRA into the future. 
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Optimised regulatory systems
Keeping pace with product and 
manufacturing developments
Supporting innovation
Providing regulatory support and 
advice to research and 
development centres
Internal capabilities
Ensuring strong internal systems, 
resources and expertise
Access to health products
Enhancing regulatory 
support to access
Better informed users
Providing current 
information to inform 
choices and decisions
2018 also brought some changes to the executive 
team at the HPRA, with the appointment of Dr Niall 
MacAleenan as Deputy Director and Head of the 
Medical Devices department and Grainne Power as 
Director of the Human Products Authorisation and 
Registration department. Both made immediate and 
important contributions in 2018. I acknowledge the 
excellence of all the HPRA staff, led by our Chief 
Executive and the members of the Management 
Committee. The year in review presented challenges 
but the significant progress and results achieved 
by the organisation in spite of those challenges are 
clearly reflected throughout this annual report. 
On behalf of the Authority, I would like to thank the 
Minister for Health, the Minister for Agriculture, Food 
and the Marine, their advisors and the staff of their 
departments for their ongoing support of the HPRA 
and its activities. 
On a personal note, as Chair, I would like to express 
my gratitude to the members of the Authority, the 
Chairs and the members of the HPRA advisory 
committees and sub-committees for their expert input 
and support throughout 2018. The contribution of the 
independent experts who share their valued opinions 
and time is of immense benefit to our organisation 
and our public health remit. 
In conclusion, the HPRA continues to be highly 
effective in addressing the public and animal health 
challenges it faces while at the same time evolving 
and enhancing its regulatory approach. As national 
competent authority, it must remain flexible and 
adaptable to the constant changes in its operating 
environment to meet the needs of patients, the wider 
public, health professionals and all those who use 
health products. 
Ms. Ann Horan 
Chairperson
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Authority Members
The Authority of the HPRA is appointed by the 
Minister for Health in accordance with the powers 
conferred by subsection 2 of section 7 of the Irish 
Medicines Board Act, 1995. The members of the 
Authority during 2018 were:
Ms. Ann Horan 
(Chairperson)
Mr. Wilfred J. Higgins Mr. David Holohan
Prof. Elizabeth Keane
Prof. Mary Horgan 
Resigned July 2018
Prof. Caitriona O’Driscoll
Mr. Brian Jones
Dr. Diarmuid Quinlan
Mr. Pat Brangan
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Management 
Committee
The members of the Management 
Committee during 2018 were:
Dr. Lorraine Nolan  
Chief Executive
 
Ms. Rita Purcell  
Deputy  
Chief Executive
Dr. J.G. Beechinor 
Director of  
Veterinary Sciences
Mr. John Lynch  
Director of Compliance
Dr. Caitríona Fisher 
Director of Quality, 
Scientific Affairs and 
Communications
Dr. Niall MacAleenan  
Deputy Director of Medical 
Devices 
Appointed February 2018
Dr. Joan Gilvarry  
Director of Human  
Products Monitoring
Ms. Lynsey Perdisatt 
Director of Human  
Resources and Change 
Mr. Kevin Horan 
Director of ICT and 
Business Services 
Ms. Grainne Power  
Director of Human 
Products Authorisation 
and Registration 
Appointed July 2018
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Chief Executive’s 
Report
This is my fourth foreword to our Annual 
Report, and I continue to be immensely 
proud of the HPRA, our people and all 
those who contribute to making it the 
effective, efficient engine that it is.
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To enable our continued success in protecting and 
enhancing public and animal health, our organisation 
has to continuously develop and evolve to deliver 
on its public service role. The year under review, 
2018, was an exciting period in terms of our ongoing 
development. A number of key projects and focus 
areas for the organisation have come to fruition or 
made critical progress. I have full confidence that 
the investment we have made in these over the 
past year and beyond will serve to strongly position 
the organisation and its staff for the future through 
enhanced capabilities, expertise and systems, and a 
more fulfilling workplace. All of these enhancements 
will enable the HPRA to continue to deliver in its 
role as a regulator of health products both used 
and manufactured in Ireland. I am confident that 
as an organisation consistently focused on change 
and enhancement, we are well positioned for the 
opportunities that 2019 and future years bring.
Health and Wellbeing
To be truly successful, an organisation must be 
healthy from the inside out. I am incredibly proud 
that 2018 saw the HPRA being awarded the IBEC 
KeepWell Mark health and wellbeing accreditation. 
The HPRA was the first public sector body to 
be awarded the national workplace wellbeing 
accreditation which demonstrates the HPRA’s 
commitment to improving the health and wellbeing of 
employees in the organisation. I am very proud of the 
HR and Change team who initiated this programme 
and colleagues across the organisation who 
contributed to its success. We will continue to work 
on our development across all areas of the KeepWell 
Mark throughout 2019 and beyond. 
Brexit
2018 was an incredibly busy year, a year which saw 
our planning and preparedness strategy continue 
for the UK’s exit from Europe and the European 
regulatory network. Given the UK has been a major 
contributor to the network and of course as a close 
neighbour, this was difficult and complex on many 
levels. However, our core remit of protecting public 
and animal health remained the key driver to our 
approach. We engaged early with our stakeholders, 
with the national action plan and with the European 
system. Regardless of the UK’s exit from Europe, we 
are confident that our focus on preparedness will 
help us to effectively manage the potential impact on 
health product supply and availability. 
Change
Throughout the year we have said goodbye to 
staff and members of our Authority and advisory 
committees, as well as welcoming new colleagues. 
Of specific mention, we have had two new members 
join our executive Management Committee. Grainne 
Power was appointed Director of Human Products 
Authorisation and Registration with oversight of the 
pre-marketing management of human medicines. 
Strategically, within this department, our operational 
focus was on increasing our footprint in terms of 
human medicines assessment capacity. In 2018, we 
made great progress on that goal. Our contribution to 
European assessments grew steadily throughout the 
year and we look forward to further progress in this 
area.
The Medical Devices department underwent 
significant change in 2018, under the leadership of 
newly appointed Head of Medical Devices, Dr Niall 
MacAleenan. Through a change programme, we 
identified a new structure comprised of technical teams 
designed to deliver a more flexible and agile approach 
to regulation. This revised model will ultimately better 
serve the public and our health system in the area of 
medical devices. This includes strengthened skills and 
capabilities in terms of embracing the opportunities 
presented by the highly innovative medtech sector as 
well as implementing the new regulatory framework 
for medical devices and in-vitro diagnostics within 
Europe during the coming years. As a responsive and 
adaptive organisation, I believe we are well equipped 
to grow and respond to the innovation and emerging 
technologies in all the sectors that we regulate. 
Contribution and Collaboration
The HPRA continues to be very busy internationally 
with a wide range of work, which includes the quarterly 
cycle of meetings at the European Heads of Medicines 
Agencies (HMA). We continue to work very closely 
with our regulatory counterparts through a wide range 
of committees and working groups at the European 
Medicines Agency (EMA) and within the HMA network, 
as well as at a bilateral level. As Chief Executive, I 
joined the HMA Management Group and also took 
on the position of Co-Chair of the HMA/CAMD joint 
task force in 2018, both of which will ensure the Irish 
perspective is presented and considered in these fora. 
The CAMD refers to the EU Competent Authorities for 
Medical Devices.  
In the ever-changing regulatory landscape, the 
development of new products, technologies, and 
production models are constantly challenging 
existing regulatory frameworks. Collaboration with 
other regulators is essential to achieve harmonised 
approaches and the comprehensive regulatory 
oversight required to facilitate the timely approval 
of new medicines and technologies while at the 
same time protecting public health. As part of our 
work within the International Coalition of Medicines 
Regulatory Authorities (ICMRA), the HPRA joined 
with a number of global authorities both to review 
and enhance existing regulatory approaches and to 
identify new regulatory tools to ensure safe and timely 
access to innovative health products. The ICMRA 
innovation project saw the HPRA co-lead one of three 
work-streams with the EMA focused on leveraging the 
outcomes of horizon scanning. This seeks to identify 
products and technologies where new regulatory 
science tools and expertise are required and will be 
of benefit, and to make use of the findings in terms of 
the regulatory enhancement. The network will aim to 
explore further innovative challenges and harmonised 
solutions on a global level. 
Towards the end of the year, we hosted the 18th 
International Conference of Drug Regulatory 
Authorities (ICDRA) on behalf of the World Health 
Organization (WHO). The conference brought together 
WHO Member States to strengthen collaboration 
and develop international consensus on regulatory 
priorities. The conference covered topics under the 
theme ‘Smart Safety Surveillance: A life-cycle approach 
to promoting safety of medical products’ and resulted 
in a number of key recommendations. 
We are both proud of and energised by our significant 
involvement at European and international levels. This 
participation affords us the opportunity to observe and 
contribute to international best practice and bring this 
home for the benefit of Irish patients.
Inspection, Surveillance and 
Enforcement
Inspection, surveillance and enforcement activities are 
key components of our role as regulator. In June 2018, 
the US FDA concluded its assessment of the HPRA 
and confirmed that our agency has the capability, 
capacity and procedures to carry out GMP inspections 
at an equivalent level. Attaining a position on the EU 
/ US Mutual Recognition Agreement list of recognised 
member states, reflects international recognition of the 
very high standards of our inspection expertise and 
processes. 
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The past year has seen the HPRA make a significant 
contribution to the fight against counterfeit and 
falsified medicines and medical devices. The outcome 
of the most recent Interpol co-ordinated Operation 
Pangea was announced in October. The HPRA, in 
partnership with Revenue’s Customs Service and An 
Garda Síochána, confirmed the detention of almost 
90,000 dosage units of illegal prescription medicines, 
valued at over €375,000. The international week of 
action targeting the online sale of falsified and illegal 
medicines saw Irish authorities join representatives 
from 61 other countries to target criminal networks 
behind the sale of falsified and illegal medicines 
via illicit online suppliers and online e-commerce 
platforms. 
Zero Gains Information Campaign
The use of falsified / fake and illegal medicines is an 
area of concern and focus. We entered somewhat 
uncharted territory with the launch of our public 
information campaign to raise awareness of the 
potentially serious side effects and health risks of 
non-medical use of anabolic steroids. The campaign 
entitled ‘Zero Gains’ incorporated online search, 
social and digital media in addition to outdoor 
and in-gym adverts. It targeted young Irish men 
and was developed in light of growing evidence 
of an increased use of anabolic steroids for body 
enhancement as well as new research showing a 
significant lack of awareness of the serious health 
complications posed by these products. 
Going Forward
Despite continued challenges and the ever changing 
and evolving environment in which we operate, there 
are many exciting opportunities ahead of us. We will 
continue to prioritise better regulation to best serve 
the Irish public, to be leaders in the regulatory space, 
to ensure appropriate access to medicines, medical 
devices and other healthcare products, and to deliver 
on our remit to protect and enhance public and 
animal health. 
Acknowledgements
I wish to acknowledge and thank the Ministers 
and staff of the Department of Health and of the 
Department of Agriculture, Food and the Marine for 
their continued support.
On behalf of the Management Committee and all our 
colleagues, I wish also to acknowledge the significant 
contribution and commitment of the members of 
the HPRA Authority and advisory committees. Their 
knowledge and advice is of great value to our agency 
and is much appreciated.
My particular gratitude to the Authority Chairperson, 
Ann Horan, for her support and counsel throughout 
the year.
Finally, to all my colleagues in the HPRA, you deserve 
huge credit for all the progress and achievements 
outlined in this report. I look forward to working with 
you all in the coming years as we continue to focus 
our efforts on delivering on our critical public and 
animal health remit.
Dr. Lorraine Nolan 
Chief Executive
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Planning for Brexit 
– Annual Update 
on Progress
The UK is due to leave the European 
Union. While the how and when they leave 
is not yet certain, any kind of Brexit will 
result in changes to the European health 
products sector and regulatory network 
as a whole. The UK withdrawal from the 
EU has potentially significant implications 
for Ireland in particular given our shared 
marketplace and the fact that many 
health products are manufactured in or 
moved through the UK to get to Ireland. 
Consequently, the HPRA has been actively 
contributing to a whole-of-Government 
response to Brexit which includes a range 
of measures to ensure the continuity of 
supply of health products in the event of a 
no-deal Brexit.  
HPRA Response to Brexit
Once Article 50 was invoked by the UK on 
29 March 2017, the HPRA commenced our 
Brexit preparedness planning. The protection 
of public health by supporting the continued 
supply of health products after Brexit was 
identified as our key strategic objective while 
also optimising our role within the European 
regulatory network.
Adopting an organisation wide approach, an 
internal task force was established to inform 
internal and external planning as well as our 
communications and engagement activities. 
As part of this approach, we developed the 
five key pillars to support delivery of our 
strategic objective and high level outputs: 
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Stakeholder 
Engagement / 
Communications
Stakeholder meetings, Q&As published, website content, one-to-one meetings with 
impacted stakeholders, presentations to industry meetings, media engagement.
Existing work where 
the UK is lead 
Member State
Committed to taking on all work where UK is the RMS and Ireland a CMS. Seeking 
newly available work under centralised system. Encouraging UK notified bodies to 
relocate to Ireland. Purpose: To maintain product on the market.
Future work to be 
allocated
Developing our capacity to bid for centralised and decentralised work to increase 
our European footprint and enhance our position as a leading EU regulator.
Leadership / Public 
Health / Advocacy
Ensuring the views of the Irish regulator are represented and understood at a 
European level. Proactively contributing to all EU Brexit meetings and engaging  
F2F with the Commission and the ENVI committee.
Internal Capability Reviewing HPRA capacity to deliver on Brexit commitments. Staffing plan submitted 
to the Department of Health.
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Key Brexit Pillars – Activities 
carried out in 2018 
Building on progress achieved during 2017, 
the following details the main activities and 
work streams delivered during 2018 in respect 
of our five Brexit pillars:
• Stakeholder Engagement / 
Communications
- There was continued implementation of 
our programme of communications and 
outreach including regular and sustained 
contact with individual manufacturers, 
industry, wholesalers and distributors, in 
addition to their representative bodies. 
Specifically we (1) contacted all MAHs 
to ensure Brexit preparedness, supply 
chain and regulatory compliance, and (2) 
engaged with wholesalers to understand 
critical products, potential supply issues 
and capacity for “buffer” stocks.
- Our detailed Brexit guidance document 
and website content were both updated 
to reflect queries received from 
stakeholders and emerging information 
from the European Commission, the EMA 
and the HMA. Updates were also made 
to the medical devices and cosmetic 
products section of the HPRA website to 
highlight potential impacts of Brexit.
- We presented at a number of industry 
seminars on the impact of Brexit and 
commenced planning for a second HPRA 
stakeholder information day in February 
2019. 
- There was regular staff communications 
in respect of Brexit planning.
• Existing Work where the UK is Lead 
Member State
- We engaged with companies to 
encourage the transfer of the RMS to the 
HPRA.
- We reviewed product exposure to the 
UK from a regulatory perspective and 
contacted companies to request that they 
transfer necessary regulatory functions to 
the EU.
- We contacted companies who have a 
large portfolio of products on the Irish 
market to understand any future barriers 
to supply and we responded to any 
potential supply issue identified.
- We provided updates in respect of joint 
labelling with the UK and met with other 
EU agencies to assess the possibility of 
multilingual labelling. 
- We concluded an agreement with the 
UK’s Veterinary Medicines Directorate for 
a work-sharing arrangement post Brexit.
• Future Work to be Allocated
- 502 RMS transfers to Ireland were 
accepted in 2018 (346 for human 
medicines and 156 for veterinary 
medicines). 
- As RMS, we progressed 25 new 
outgoing MRP/DCP applications for 
human medicines. We also progressed 
25 new MRP/DCP veterinary product 
applications. 
- We were appointed rapporteur / co 
rapporteur for 12 centralised human 
medicines while also being appointed 
rapporteur for 6 centralised veterinary 
products. 
- We acted as co-ordinator for 78 EMA 
scientific advice procedures for human 
medicines and three for veterinary 
medicines.
- Support was provided to UK based 
notified bodies assessing their regulatory 
requirements as a result of Brexit and we 
received an application from one notified 
body for designation in Ireland. 
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• Leadership / Public Health / Advocacy
- We participated in all Commission 
seminars and other EU meetings 
to advocate and promote greater 
understanding of the potential impact of 
Brexit for Ireland.
- We led discussions at an EU level for 
the acceptance of dual labelling and for 
a pragmatic approach to contingency 
planning. 
- There was regular engagement with 
officials at the Department of Health and 
the Department of Foreign Affairs and 
Trade.
- We engaged at a national level with the 
Revenue Commissioners with a view to 
minimising potential customs impact.
- We liaised with IDA Ireland, IBEC and 
industry representative bodies, and other 
stakeholders as appropriate.
• Internal Capability
- Our Brexit planning includes due 
consideration of potential staffing 
requirements and we continued to work 
closely with the Department of Health on 
this matter. 
- We are committed to ensuring that we 
have sufficient staff levels to manage the 
implications of Brexit and throughout 
2018 we devoted expert staff resources 
to this important area through a 
combination of allocating existing staff as 
well as some new staff. 
Contingency Planning for  
No-Deal Brexit
During the course of 2018, our Brexit planning 
was based on a no-deal outcome as of 29 
March 2019 without a transition period. 
Consequently, all our advice and direction to 
industry stakeholders was that they must carry 
out all their regulatory changes before that 
key date. 
From late 2018, the HPRA moved from 
operational planning to Brexit contingency 
planning under the following headings:
• Regulatory compliance of medicines and 
clinical trials authorised on the Irish market;
• Supply chain management and stock levels;
• Exempt medicinal products;
• Shortages protocol;
• Development of a list of essential 
medicines;
• Communications with stakeholders;
• Medical devices with UK CE marks;
• Veterinary medicines and engagement with 
the Department of Agriculture, Food and 
the Marine;
• Engagement within the European network.
While the European Council subsequently 
agreed to an extension of the Article 50 
process until 31 October 2019, with the 
possibility that the UK will exit prior to that 
date if its Parliament ratifies the “Withdrawal 
Agreement”, the risk of no deal has not 
been eliminated. For that reason, our Brexit 
contingency planning will continue throughout 
2019 for as long as it is deemed necessary. We 
will report fully on progress and achievements 
in our 2019 Annual Report. 
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Human Medicines
The HPRA grants licences for medicines 
subject to a review of their safety, quality 
and effectiveness and continuously monitors 
their use once they become available on 
the Irish market. We also approve and 
monitor clinical trials, inspect and license 
manufacturing sites and wholesalers, and 
investigate activities associated with the 
illegal supply, manufacture or advertising  
of medicines.
Authorisation and Registration
• Prior to a new medicine being placed on the 
Irish market, it must be assessed and authorised 
(licensed) by the HPRA or by the European 
Medicines Agency (EMA) in conjunction with the 
European Commission. The assessment involves 
establishing that a medicine’s health benefits 
outweigh its known risks. Where this is the case, it 
may be granted a marketing authorisation.
 There are a number of routes through which a 
product can be authorised by the HPRA. These 
include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). Both MRP and DCP involve 
the simultaneous submission of applications in a 
number of EU Member States. 
 The centralised route is coordinated by the EMA 
and results in an authorisation which is granted 
by the European Commission and is valid across 
Europe. The assessment is carried out by Member 
States appointed as lead assessor (rapporteur), joint 
lead assessor (co-rapporteur) and peer reviewer, 
with input also from all other Member States.
 During the year in review, the total number of new 
medicines authorised in Ireland was 376. The 2018 
figure incorporates:  
– 66 new national applications which includes 60 
parallel import applications; 
– 35 applications made under the MRP and 168 
applications made under DCP. The HPRA acted as 
reference (lead) Member State for the assessment 
of 18 of the DCPs;
– 5 rapporteurships and 11 co-rapporteurships 
under the centralised route; 
– An additional 91 medicines authorised through 
the centralised route where the HPRA was neither 
rapporteur nor co-rapporteur.
• The EMA operates a scientific advice and protocol 
assistance procedure system to applicants on the 
appropriate tests and studies in the development 
of a medicine. This is designed to facilitate the 
development and availability of high-quality, 
effective and acceptably safe medicines for the 
benefit of patients. During 2018, the HPRA acted as 
co-ordinator for 78 EMA scientific advice requests 
across a broad range of conditions.
 Our national scientific and regulatory advice 
procedure functions in a similar way and assists 
commercial and non-commercial entities making 
applications for clinical trial authorisation or 
marketing authorisations. This service complements 
advice which we provide on earlier stage product 
development through the Innovation Office. During 
the year, we completed 10 requests under this 
procedure.
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• Participation in clinical trials can enable patients to 
benefit from new and promising therapies.  During 
2018, we issued 100 new clinical trial applications. 
Of these, 22 applications were voluntary 
harmonisation procedures for clinical trials with 
the HPRA acting as lead Member State for one of 
these co-ordinated work-sharing assessments for 
multinational clinical trials.  
• Reclassification of the legal status of medicines aims 
to increase the number of medicines available to 
patients without prescription where it is safe to do 
so. This year: 
– Medicines for the treatment of hay fever and 
fungal skin infections were authorised for non-
prescription, pharmacy-only sale.
– A medicine containing folic acid and seven 
medicines for the treatment of skin conditions 
were authorised for sale in pharmacies and non-
pharmacy outlets (general sale).  
• In 2013, the HPRA commenced publication of 
a list of interchangeable medicines to facilitate 
generic substitution by pharmacists and to allow for 
reference pricing by the Health Service Executive 
(HSE). By year end, the interchangeable medicines 
list included 63 active substances.
• Medicine shortages have been an ongoing 
concern globally and in Ireland for some years. In 
September, we launched a new national initiative 
to better manage medicines shortages and their 
impact on Irish patients. The Medicine Shortages 
Framework is a collaborative initiative that brings 
together key players in the health sector with the 
aim of developing strategies to mitigate the effect 
of shortages in Ireland so that patient health is 
protected. See page 42 for further information on 
how the introduction of the framework is helping to 
manage shortages.
 In addition to the framework, and in the context 
also of potential shortages arising from the 
response of companies to the exit of the UK from 
the EU, we are progressing the option for marketing 
authorisation holders (MAHs) to utilise multilingual 
labelling. During 2018, we published an updated 
version of our ‘Guide to Labels and Leaflets’ and 
developed a procedure (which will be introduced 
in early 2019) to assist MAHs develop multilingual 
labelling with other Member States and to maintain 
joint labelling with the UK.
 An additional mechanism used by the HPRA to aid 
continuity of supply to the market place in the event 
of a medicine shortage includes the granting of a 
temporary authorisation for a batch of a medicine 
known as a ‘batch specific request’. In 2018, there 
were 100 requests received.
• We continued to monitor the numbers of 
unauthorised products notified to us through the 
exempt medicinal product scheme. One aspect 
of our approach to reducing the risks to patients 
is to actively seek new marketing authorisation 
applications for high-volume products currently 
being imported through this scheme. Two such 
authorisations were issued in 2018.
 While various factors can lead to changes in the 
volume of packs notified to the HPRA on an annual 
basis, it is likely that market shortages were a 
contributory factor in the annual increase recorded 
in 2018.
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Safety and Quality
• Under the SCOPE project (Strengthening 
Collaboration for Operating Pharmacovigilance in 
Europe) created to support pharmacovigilance in 
the EU following legislative requirements that came 
into effect in June 2012:
– There was continued collaboration with 
stakeholders concerning the distribution of joint 
communications to healthcare professionals.
– We engaged with IPPOSI, as part of its pilot 
Patient Education Programme specifically 
tailored for Irish patient communities, to provide 
medicines safety input for patient training 
materials. Colleagues also provided support 
for future planning for the next iteration of the 
IPPOSI programme.
– The HPRA’s online ADR reporting platform was 
utilised to facilitate practical student learning as 
part of EUPATI face to face training.
• Following the introduction of changed reporting 
rules for the EU’s Eudravigilance database 
of adverse reactions in late 2017, and the 
simultaneous update of the HPRA’s adverse reaction 
database, we continued to refine our processes to 
manage the increased volume of reports and report 
reconciliation activities. 
• Adverse reactions reports assist the HPRA, in co-
operation with pharmacovigilance professionals in 
Europe and further afield, to look for new types of 
reactions or changing trends in reporting. Reports 
submitted to the HPRA in many instances arise 
Authorisation and registration: Key figures
2016 2017 2018
Classification queries / reviews 130 152 93
Scientific advice 
 Lead in EMA scientific advice:
 National scientific advice (commenced in 2016)
51
13
47
6
78
10
Clinical trial applications 108 96 100
Voluntary Harmonisation Procedures (multinational clinical trials) 
 Lead
 Participating member state
8
22
5
14
1
22
New medicines applications for marketing authorisations 
 National (including new parallel imports)
 Mutual recognition and decentralised RMS
 Mutual recognition and decentralised CMS
 Centralised Rapp/Co-Rapp/Peer reviewer
71
12
365
20
104
10
370
12
66
25
178
19
Traditional herbal medicinal products under the simplified registration 
scheme
9 4 4
Homeopathic medicines under the simplified rules scheme 1 2 3
Variations to marketing authorisations (Type IA, IB, II) 13,837 11,600 10,077
Articles 45 and 46 - Variations to Update Product Information 1 2 1
Renewals of marketing authorisations 351 248 597
Transfer of marketing authorisation holder 209 208 801
Manufacturers 103 111 127
Manufacturers of investigational medicinal products 55 52 63
Wholesalers 318 348 358
Registrations for active pharmaceuticals ingredients
 Manufacturers
 Importers
 Distributors
21
41
49
28
59
81
29
67
87
Brokers 3 9 8
Export certificates 1,274 1,375 1,319
Exempt medicines programme for notification of unauthorised medicine 
import 
1,827,047 
packs
1,961,541 
packs
3,209,365 
packs 
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from concerns occurring during observation of an 
unexpected and / or unwanted event, in the context 
of use of a medicine. They also include known 
adverse reactions, such as those described in the 
product information. This year:
– 10,398 adverse reactions reports were received 
associated with the use of human medicines. 
This represents a 138% increase in overall 
reporting rates compared with 2017. The 
legal obligation for MAHs to report all serious 
adverse reaction reports of which they become 
aware was extended in November 2017, to 
include non-serious reports. This change to 
reporting requirements largely accounts for 
the increase in the volume of reports received. 
However, additional complexities associated with 
reporting through the EudraVigilance system 
also impacted significantly on workload and 
interactions necessary to support case processing, 
management of duplicate reports and data 
quality.  
Adverse Reaction Reports
12,000
10,000
8,000
6,000
4,000
2,000
0
2014
2,8
84
2015
2,8
10
2016
3,2
64
2017
4,4
02
2018
10
,39
8
– In the context of the changed reporting 
requirements, 92% of all adverse reaction reports 
received by the HPRA in 2018 were reported 
by MAHs, with a further 0.5% reported in the 
context of ongoing clinical trials. It is important 
to note that these reports will have initially been 
notified to companies by healthcare professionals, 
patients or consumers. 
– Medicines subject to additional monitoring 
accounted for 24% of the reports submitted.
– The medicines most frequently included in reports 
to the HPRA accounted for 81% of the adverse 
reaction reports received in 2018 (see table). It is 
important to note that the place of a medicine on 
this list cannot be taken as an indicator of safety 
or risk. The number of reports received cannot be 
used as a basis for determining the incidence of a 
reaction as neither the total number of reactions 
occurring, nor the number of patients using a 
medicine, is known.  
Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines, 
monoclonal antibodies and endocrine 
medicines
5,302
Psycholeptic medicines 646
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals 
and immunoglobulins
497
Medicines for the treatment of bone 
disease 355
Medicines for the treatment of 
Parkinson’s disease 353
Cardiovascular medicines, including 
antihypertensives and lipid lowering 
agents
346
Vaccines 295
Medicines for the treatment of 
epilepsy and neuropathic pain 248
Antithrombotic medicines, including 
anticoagulant and anti-platelet 
medicines
248
Medicines regulating parathyroid 
hormone levels 227
– Of the new adverse reaction reports received by 
the HPRA in 2018, 252 patients were reported to 
have died while on treatment. The table below 
outlines the medicines or class of medicines 
associated with the highest number of reports. In 
many of these cases, the patients had significant 
underlying illness and were treated with multiple 
medicines and/or surgery which may also have 
contributed to the outcome. In addition, many 
of these cases were influenced by disease 
progression or other complications unrelated to 
the medicine. The majority were associated with 
medicines subject to close monitoring, those used 
in the management of severe underlying medical 
conditions, in patient support programmes and 
special patient monitoring programmes.
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Suspect Medicine(s) /    
Class of Medicines
Number of 
Reports*
Antineoplastics, including 
immunomodulating medicines, 
monoclonal antibodies and endocrine 
medicines
109
Psycholeptic medicines 44
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals and 
immunoglobulins
24
Antithrombotic medicines, including anti-
coagulant and anti-platelet medicines 22
Medicines for the treatment of epilepsy 
and neuropathic pain 12
Medicines for the treatment of depression 10
Cardiovascular medicines, including 
antihypertensives, anti-arrhythmic and 
lipid lowering agents
9
Anaesthetic, opioid and anti-migraine 
medicines 8
Medicines for the treatment of 
gastrointestinal conditions 6
Systemic corticosteroid medicines 5
* Please note that in some cases treatment may have 
involved more than one medicine from the groups 
listed.
• The HPRA also plays a key role in monitoring 
the safety of medicines on the Irish market via 
our vigilance assessment and risk management 
activities. This incorporates our contribution to the 
work of the Pharmacovigilance Risk Assessment 
Committee (PRAC) at the EMA. During 2018, the 
HPRA:
– Continued our involvement in the work-sharing 
initiative for signal detection within the EU acting 
as lead Member State for the monitoring of 53 
nationally-authorised active substances. Serving 
as PRAC rapporteur, we were also responsible for 
the further management of any signals detected 
in relation to 46 centrally authorised medicines 
(containing 32 active substances / combination of 
active substances).  
– Participated in the EU periodic safety update 
report (PSUR) single assessment procedure, 
contributing to the evaluation of 900 PSURs and 
leading the single EU assessment for 28 of these 
procedures.
– Participated as a concerned Member State in nine 
ongoing safety referrals, eight of which reached a 
conclusion during the year.
– Contributed to the review of 253 risk 
management plans (newly approved or updated) 
submitted via national, mutual recognition, 
decentralised and centralised procedures. We 
also provided assessment input to 518 post 
authorisation safety procedures (safety study 
protocols, reports and other post authorisation 
safety-related measures).
• The HPRA continues to engage with multi-
stakeholder groups, including patient and 
clinical practice representatives, to facilitate 
clinical readiness at national level for new 
recommendations on the safe and rational use of 
medicines following major EU benefit-risk reviews. 
During 2018, this included both (1) the ongoing 
implementation of valproate key risk minimisation 
recommendations and (2) the introduction 
of fluoroquinolone key risk minimisation 
recommendations into clinical practice.
• Also during 2018, the HPRA, in collaboration with 
researchers from the RCSI, successfully secured a 
HRB Applied Partnership Award, bringing together 
the HPRA as knowledge user and RCSI as academic 
researcher, to fund research into optimising 
effectiveness of risk minimisation measures to 
prevent harms from teratogenic medicines. 
• The inspections and audits programme focuses 
on ensuring industry compliance with relevant 
standards and legislation. This year, there were: 
– 104 good manufacturing practice (GMP) 
inspections were conducted at sites that produce 
human medicines or active substances.
– 183 good distribution practice (GDP) inspections 
at wholesalers and distributors;
– 10 good clinical practice inspections at 
investigator or sponsor sites;
– 7 pharmacovigilance inspections;
– 4 bioanalytical inspections;
– 3 regulatory compliance inspections were 
conducted at the premises of marketing 
authorisation holders to determine the level of 
compliance with the legal requirements for the 
marketing and advertising of medicines. 
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• The risk based sampling and analysis programme 
is part of our monitoring of the quality and safety 
of medicines on the Irish market or which are 
manufactured in Ireland for export. It involves the 
analytical testing of products and / or examination 
of their packaging and labelling. 358 samples were 
taken under the programme in 2018. This included:
– Examination of the packaging and labelling of 
126 medicines and other products available 
on the Irish market. 15 non-compliances were 
identified including Braille-related issues, 
non-compliant packaging and labelling, and 
the absence of updated safety information. 
Appropriate follow-up actions were taken in each 
case.
– Additionally, 205 medicines and other product 
samples for human use were sent for analytical 
testing during the past year. Although the 
majority were found to be compliant with their 
specifications, a number of out of specification 
results were also obtained. The most frequent of 
these related to product appearance not being in 
accordance with the registered specification, and 
nitrosamine impurity levels in sartan-containing 
medicines being above the required limits. Again, 
appropriate follow-up actions were taken in each 
case.
– Testing of a small number of investigational 
medicinal products was carried out and, where 
required, related follow up was initiated.
• The quality defect and recall programme 
investigates, on a risk basis, reports of suspected 
quality defects in medicines and in their related 
active substances. It also co-ordinates recalls from 
the Irish market. Quality defects pertaining to 
925 medicines for human use were reported or 
identified in 2018. The risk classifications that were 
assigned, along with the corresponding figures 
for the previous two years, are outlined in the 
accompanying table.          
Year 2016 2017 2018
Critical quality defects 119 124 325
Major quality defects 331 196 280
Minor quality defects 382 327 308
Number of reports not justified 3 3 12
Total Number Quality Defects 835 650 925
 As in previous years, companies (52%), including 
manufacturers, distributors and/or authorisation 
holders, and other competent authorities (41%) 
were the primary sources of reports received. 
• In certain cases, it may be deemed necessary to 
withdraw, or recall, medicines from the Irish market 
in order to protect public health. During the year, 
196 medicine recalls occurred representing a 73% 
increase when compared to 2017. Overall, the most 
common causes of recalls were:
Cause of Recall Number of 
Recalls
Lack of sterility assurance 80
Contamination issues 55
Erroneous distribution activities 22
Stability issues 11
Adverse reactions or changes in benefit/
risk ratio 6
Primary/secondary packaging component 
issues 6
• The HPRA monitors the sale of certain consumer 
health products in outlets such as grocery 
shops, health food shops and, where necessary, 
pharmacies. There were 11 cases investigated, 
some of which involved multiple products. Of these,
– nine cases related to the sale of medicines that 
did not carry a valid registration number or 
authorisation number for the Irish market resulting 
in 18 medicines being removed from sale and 
necessary follow-up actions being taken; 
– two cases related to the classification status of the 
products.  
 In addition, 80 queries linked to the sale of health 
products in Ireland were addressed.
• The advertising compliance programme monitors 
and reviews advertising and promotion activities 
carried out by the industry in relation to human 
medicines for compliance with the legislation. 
In total, 310 advertisements were reviewed, and 
non-compliances, including both major and minor 
issues, were identified in 37 of these. In addition, 
four other minor deficiencies related to advertising 
activities were identified during inspections of 
marketing authorisation holders. In all cases, we 
oversaw the necessary corrective and/or preventative 
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actions, where relevant. (The HPRA has published 
a standalone report available from our website that 
provides an overview of the main elements of the 
advertising compliance programme for 2018). 
• Under our enforcement programme:
– The HPRA detained 619,213 dosage units 
(including tablets, capsules and vials) of falsified 
and other illegal medicines in 2018, compared 
to 948,915 units in 2017. The products detained 
included sedatives (36%), erectile dysfunction 
medicines (18%) and anabolic steroids (16%). 
There were 4,532 enforcement cases initiated, 
compared to 3,866 in the previous year.
– Several HPRA operations took place in 
conjunction with An Garda Síochána, Revenue 
Customs Service and the Food Safety Authority 
of Ireland. These operations resulted in the 
detention of over 40,000 capsules, tablets and 
vials containing anabolic steroids in the Dublin 
area. 
– We initiated 10 prosecution cases and issued 
14 voluntary formal cautions. Prosecutions are 
taken where the HPRA considers that there is a 
significant risk to public health or where there are 
persistent non compliances. The prosecutions 
related to the unauthorised supply of prescription 
medicines, including falsified anabolic steroids, 
erectile dysfunction products and sibutramine 
containing medicines. We also support 
prosecutions brought by the Director of Public 
Prosecutions in relation to the illegal supply of 
medicines.
– The HPRA, in conjunction with Revenue’s 
Customs Service and An Garda Síochána, 
detained over 90,000 units of unauthorised and 
falsified medicines in Ireland, valued at over 
€375,000, as part of the Interpol-coordinated 
Operation Pangea XI. The products detained 
included significant volumes of anabolic steroids, 
sedatives, analgesics and erectile dysfunction 
medicines. Nationally, the operation also resulted 
in the investigation of 56 websites, with 10 
e-commerce advertisements and 14 social media 
pages being taken offline. Operation Pangea 
XI was an international week of action across 61 
countries to tackle the online sale of counterfeit 
and illicit medicines and to highlight the dangers 
of buying medicines online.
Legislation and Regulation
• The new Clinical Trial Legislation, Regulation EU No 
536/2014, is planned to be implemented during 
2020, when the development of the Clinical Trial 
Information System (CTIS) has been completed by 
the EMA. 
 The following national activities were progressed 
during 2018:
– We engaged with the Department of Health 
regarding the implementation of the Regulation 
and the development of national legislation; 
– We commenced a pilot project for simultaneous 
submission of applications to both the HPRA 
and ethics committee which enables preparation 
for implementation of the Regulation. Guidance 
and templates for sponsors are available on the 
website;
– We actively participated in the European 
voluntary harmonisation project which is similar to 
the approval process for clinical trials under the 
planned new legislation (see page 15).
• As of 9 February 2019, under the Falsified 
Medicines Directive, the majority of prescription 
medicines must carry special safety features in 
the form of an anti-tamper device and a barcode 
containing ‘unique identifiers’ (including a serial 
number) to enable the authenticity of the pack to 
be checked prior to dispensing. In 2018:
– Work towards national implementation and 
introduction of these measures continued. This 
was led on behalf of the industry and pharmacy 
sector by the Irish Medicines Verification 
Organisation (IMVO). We met regularly with the 
IMVO for updates on implementation of the 
necessary repository and software systems; 
– We contributed to a Department of Health 
led group of stakeholders which met regularly 
to monitor progress on implementation both 
nationally and across the EU;
– The EU working group on supervision of the 
national repositories of unique identifiers, led by 
the HPRA, continued to work through its plan for 
the project. 
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Stakeholders and Partners
• In April, the HPRA appeared before the Joint 
Committee on Health which was discussing 
foetal anti-convulsant syndrome. The HPRA’s 
Director of Human Products Monitoring and our 
Pharmacovigilance and Risk Management Lead 
were in attendance along with representatives from 
the Foetal Anti-Convulsant Syndrome (FACS) Forum 
and the HSE. The HPRA provided an update on 
the regulatory aspects of the medicine valproate 
(Epilim). This included details of the most recent 
European safety review and our collaboration at a 
national level with representatives from the FACS 
Forum, the Department of Health, the HSE and 
the Pharmaceutical Society of Ireland to facilitate 
timely and effective implementation of the new 
recommendations arising from the review. The 
HPRA also provided responses to a number of 
queries from the Committee members.
 In September, the HPRA’s Clinical Assessment 
Manager, accompanied by our Director of 
Compliance, appeared before the Committee to 
address the matter of the authorisation of medicines 
in the context of the planned introduction of the 
termination of pregnancy legislation in late 2018. 
The HPRA representatives provided an update 
to the members and responded to a number of 
queries linked to this matter. 
• As in recent years, the HPRA delivered a 
programme of presentations and talks at 
external stakeholder events such as meetings, 
seminars, conferences and training courses. 
Such presentations provide stakeholders such 
as healthcare professionals and regulatory 
professionals with access to relevant, up-to-
date information. In addition, a programme of 
presentations was delivered to undergraduate and 
postgraduate students studying courses related to 
the role of the HPRA. A full list of all presentations 
delivered during 2018 relevant to human medicines 
is provided in Appendix 2.
• Publications and Information 
– The Drug Safety Newsletter provides important 
safety information to healthcare professionals 
with hyperlinks to product information and 
other relevant documents on the HPRA and 
EMA websites. Six issues of the newsletter were 
published and distributed to registered healthcare 
professionals, all of which are accessible from 
the HPRA website. A full index of topics covered 
during the past year is included in Appendix 3.
– Risk communications: 
- During 2018, 90 new or updated educational 
materials were approved by the HPRA in 
addition to 28 direct healthcare professional 
communications. 
- The PRAC monthly agendas, minutes, meeting 
highlights, notifications of safety reviews and 
signals were also made available via our website.
– There were a number of articles provided for 
inclusion in the monthly MIMS (Ireland) publication 
in addition to articles for the Irish Medicines 
Formulary. The full list of topics covered in these 
articles is included in Appendix 3. 
– The Medicinal Products Newsletter provides 
regulatory news and updates for those working 
in the pharmaceutical industry. Three editions 
were published on our website in 2018 and are 
available to download from the ‘Publications’ 
section. 
– Two new guidance documents relevant to human 
medicines were published in 2018 and are 
available to download from our website:
- Guide to the sale of paracetamol-containing 
medicines by non-pharmacy retailers; 
- Guide to new applications and variations to 
wholesale distribution authorisations. 
– The Medicines Shortages Framework document 
was published online in September (see page 42). 
• HPRA information seminars and training events 
provide regulatory guidance and updates to a 
range of stakeholders. Our programme of events in 
2018 included an information day on good clinical 
practice (GCP) for investigational medicinal product 
trials. This event, which was attended by over 130 
delegates, was held in Dublin in October.
• Following on from related activities in 2017, we 
published a research paper entitled ‘Knowledge 
of adverse drug reaction reporting and the 
pharmacovigilance of biological medicines: A 
survey of healthcare professionals in Ireland’ in 
the online journal Biodrugs. A poster of the same 
title was presented at the annual Prescribing 
and Research in Medicine Management meeting 
in London. Additionally, we published a review 
entitled ‘Regulation of biosimilar medicines 
and current perspectives on interchangeability 
and policy’ in the European Journal of Clinical 
Pharmacology. 
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25 Years of 
Medicines Safety 
Monitoring
Dr Joan Gilvarry,  
Director of Human 
Products Monitoring
In May 2019, Dr Joan Gilvarry retired from 
the HPRA following an eminent career in 
medicines regulation, which first started 
when she crossed the threshold of the 
National Drugs Advisory Board (NDAB) in 
1993. During her 26 year career, she has 
been a driver of and witness to the many 
advances that have taken place in national 
and European medicines regulation – most 
notably in the pharmacovigilance and safety 
monitoring of medicines. 
When Dr Gilvarry joined the NDAB there 
were around 50 employees with a role to 
assess human and veterinary medicine 
applications and to provide advice to the 
Minister for Health. The Minister, who had 
the legislative remit to license medicines at 
that time, would consider the advice and then 
make the decision to authorise the medicine 
or not. In 1996, the NDAB was replaced by 
the Irish Medicines Board (IMB), which was 
established in legislation with the statutory 
powers to regulate and licence both human 
and veterinary medicines. Over the following 
decade, the IMB’s regulatory remit expanded 
to include a wide range of other health 
products. It would ultimately become the 
Health Products Regulatory Authority in 2014 
which today employs some 350 people. 
In parallel, Dr Gilvarry’s career progressed. 
From being one of just four medical assessors 
in 1993, she was appointed Medical Director 
in 2000. She recalls the vast changes in 
medicines regulation that have brought 
tremendous benefit to patient safety during 
her lengthy career. When she joined the 
NDAB, all the applications were assessed 
in hard copy format and fax machines 
were the fastest means of communication. 
‘Essentially, it was a lot of big, big boxes and 
folders of data arriving with new medicine 
applications that required quality, safety 
and efficacy assessments. There is no doubt 
that the evolution of technology, and the 
innovations brought about by a connected 
IT infrastructure, revolutionised our way of 
working and brought immense efficiencies to 
the assessment process,’ she says.
‘At that time, the organisation consisted 
of the human medicines team, veterinary 
medicines team, pharmaceutical assessors and 
the all-important support staff for these areas. 
There were just two people - including my 
colleague Niamh Arthur who I have worked 
with and who has supported me throughout 
my 26 years here - dedicated to adverse 
reactions and assessing safety reports. 
Adverse reactions were reported through a 
yellow card freepost system. The technology 
to support case report processing was first 
introduced around 1996, with electronic 
reporting then established in 2005.’
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In 1996, when the NDAB became the IMB, Dr 
Gilvarry says this ‘marked a significant change 
in medicines regulation’ in Ireland and across 
Europe. This coincided with changes to the 
European legislative framework to enhance 
and develop common and harmonised 
assessment procedures while maintaining a 
reactive approach to the safety monitoring. 
In comparison, ‘the risk/benefit monitoring is 
now significantly integrated into the product 
life cycle and there is substantive sharing of 
information and data.’
With the establishment of the European 
Medicines Agency in 1995, there began 
greater sharing of expertise and information 
between regulators across all Member States. 
It ultimately brought about significant changes 
in pharmacovigilance between 2003 and 
2004 and Ireland got the opportunity to play 
a more proactive role with an approach that 
enabled EU wide licensing of and monitoring 
of medicines. The positive benefit of EU 
participation was advanced further with more 
knowledge sharing platforms for establishing 
and monitoring the safety of medicines. The 
EU Commission also reviewed the conduct 
of pharmacovigilance across Europe and 
after a consultation process published new 
legislative requirements in 2010 which 
were implemented in July 2012. This Dr 
Gilvarry says was a ‘sea-change’ in the safety 
monitoring of medicines in Ireland and across 
the EU with probably the most significant 
change being the establishment of a new 
committee - the Pharmacovigilance Risk 
Assessment Committee (PRAC). This resulted 
in structures for formalised pan-European 
assessments and monitoring of medicines, 
and recommendations that were legally 
binding. 
The HPRA has been a very active contributor 
to the enhanced process, leading and 
supporting EU wide medicine reviews as well 
as providing expert staff to all appropriate 
EU working groups. Here Dr Gilvarry pays 
tribute to her colleague Dr Almath Spooner, 
the Pharmacovigilance and Risk Management 
Lead at the HPRA for her very strong voice 
as Vice-Chair of the PRAC for some six years 
and advocating strongly for Irish patients. 
Fundamentally, the PRAC ‘enabled a 
progressive shift from reactive safety medicine 
monitoring to a much more proactive model.’
Many safety reviews (referrals) have been 
conducted across the EU over the past years 
with the HPRA playing a significant role in 
their outcome in the interests of public health 
and Irish patients. These include reviews 
of fluoroquinolone antibiotics, valproate 
containing medicines, oral contraceptives and 
gadolinium contrast agents to name but a 
few. 
Of particular note, the referral process for 
fluoroquinolones included the PRAC’s second 
ever public hearing, which was hosted at the 
EMA in June 2018. These public hearings 
enable regulators to engage EU citizens in 
the oversight of medicines and to listen and 
learn from their views and experiences. The 
patient input was a key element for the PRAC 
as it carried outs its review and resulted in 
a fully informed assessment based on the 
scientific and clinical data in addition to direct 
patient testimonies. The PRAC’s considered 
decision, published in October 2018, was 
that fluoroquinolone antibiotic use should 
be further restricted and the information 
provided to patients on potential adverse 
reactions should be expanded to emphasise, 
in particular, the possibility of persisting 
effects. The HPRA immediately moved to 
implement the PRAC recommendations at a 
national level here with a multi-stakeholder 
meeting held in December with relevant 
healthcare professionals and representatives 
from the health service and patient 
organisations.
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Dr Gilvarry also cites Valproate as another 
medicine where the voice of EU citizens 
– including patients, carers, healthcare 
professionals and academia – was critical in 
the PRAC evaluation of the medicine and 
clearly supplemented the available scientific 
evidence. First reviewed by the PRAC in 2013, 
a further European-wide review commenced 
in 2017, to assess the measures taken to 
increase awareness and reduce exposure to 
valproate use during pregnancy. This review 
featured the first ever EMA public hearing 
held in autumn 2017, with contributions 
from patients and carers from across Europe 
including representatives from Ireland. The 
subsequent recommendations and measures 
were announced by the PRAC in early 2018 
and included the introduction of important 
new contraindications, strengthened warnings 
and further measures to prevent valproate 
exposure during pregnancy, including a 
new pregnancy prevention programme. 
Throughout 2018, the HPRA worked with 
the HSE, clinical leads, the Pharmaceutical 
Society of Ireland (PSI) and the Department 
of Health to facilitate the timely and effective 
implementation of the new recommendations 
nationally and, crucially, to support their 
successful introduction into everyday clinical 
practice. 
Speaking on leaving her role where she has 
overseen the introduction and development 
of a more inclusive and sophisticated 
pharmacovigilance model, Dr Gilvarry states 
that there are more opportunities to enhance 
the safety monitoring of medicines with new 
innovations in technology and new ways to 
optimise communication and to enhance and 
coordinate the vigilance frameworks across 
the EU. This combined with strong legislation 
and appropriate regulation augers well for the 
future. 
According to Dr Gilvarry, the EU (EMA) and 
the committee structures enable such positive 
developments but explains, “the EMA is 
the machine behind us, they co-ordinate 
and give guidance and support on issues 
but the scientific assessments and national 
expertise comes from the member states.” 
In this regard, she states that the HPRA has 
‘punched above our weight at an EU level’ 
over many years.  
‘The decisions taken are science driven and 
always in the public health interest. With 
advancements in communication methods 
over the years we can now quickly implement 
new prescribing advice, make instant contact 
with the medical and pharmacy professionals 
that prescribe and dispense the medicines, 
very importantly, the patients taking the 
medicines and their organisations.
‘There have been many milestones over the 
years and some difficult and challenging 
safety issues. Our focus, however, must always 
be on ensuring the best possible health 
outcomes and it is incumbent on regulators 
to act decisively and in a timely manner on 
all information that is available to protect 
patients. This will continue to be the central 
driving force of medicine safety monitoring 
and regulatory action and I’m leaving a 
fantastic team behind me who can bring 
pharmacovigilance onwards and upwards over 
the coming years.’
Medical 
Devices
As the national competent authority for 
medical devices, the HPRA carries out a range 
of registration, surveillance, monitoring and 
compliance activities. Our aim is to ensure that 
these health products perform as intended and 
do not compromise the health and safety of the 
patient or the person using them.
Authorisation and Registration
• The HPRA is focused on ensuring effective and 
consistent designation and oversight of notified 
bodies at national and European level. In 2018, we:
– Assessed a number of applications from 
organisations seeking to be designated as 
notified bodies in Ireland under both the new 
Regulations and the existing Directives; 
– Continued our schedule of oversight of the 
notified body in Ireland based on ongoing 
assessment, surveillance and observed audits;
– Provided expert assessors to participate in five 
EU joint assessments of notified bodies based in 
other European countries; 
– Continued to provide leadership and support 
development of EU coordination of notified body 
designation and oversight by acting as the deputy 
chair for the EU Notified Body Operations Group 
(NBOG);
– Identified and prioritised development of systems 
and resources at national and EU level to allow 
timely and effective designation of notified bodies 
required under the new EU Device Regulations 
(EUDR). 
• Supporting innovation and research of new 
technologies is a key strategic priority for the HPRA 
devices team. In 2018, this involved:
– The review of applications to conduct clinical 
investigations of medical devices in Ireland. The 
number of clinical investigations remained stable 
with nine new applications and 15 amendments 
to ongoing investigations received in 2018. HPRA 
anticipate that numbers will increase when the 
new EU Regulations are implemented; 
– The HPRA continue to focus on this area to 
ensure regulatory requirements and processes are 
clear and accessible to potential applicants;
– Encouraging engagement during product 
development and innovation of medical 
technologies. We met with 18 groups of 
innovators (13 preliminary and five pre-submission 
meetings);
– Supporting the work of the HPRA Innovation 
Office on medical devices queries received.
– Presenting and participating in innovation 
sessions at a variety of conferences and 
workshops including the Euro PCR conference in 
Paris. 
25
• Manufacturers of certain medical devices and in 
vitro diagnostics are required to register with the 
HPRA. In 2018, the HPRA received 50 registrations 
of new organisations manufacturing these products 
in Ireland. A total of 831 medical devices were also 
registered. HPRA anticipate increased numbers of 
organisations and devices will be registered in the 
run up to the UK exit from the European Union. 
Safety and Quality
• We continue to develop and reinforce our market 
surveillance activities, with particular emphasis on 
proactive rather than reactive actions. Of note in 
2018:
– We utilised a lifecycle market surveillance strategy 
and planning mechanism to ensure continued 
safety and performance of devices throughout 
their lifetime; 
– We led or participated in various elements of 
both technical work packages of the EU Joint 
Action on Market Surveillance (JAMS) of medical 
devices initiative which is funded by the European 
Health Programme and aims to develop market 
surveillance activities; 
– A total of 38 COEN notices were sent to the 
European network relating to medical device 
compliance concerns;
– Two information notices were published in 
relation to medical device issues, relating to the 
use of HIV self-tests and food intolerance tests; 
– There were 1,604 market surveillance cases* 
undertaken in 2018. The increase in cases, when 
compared to 2017, is in part the result of a 
37% increase in the number of EU notifications 
received by the HPRA relating to notified body 
certificates.
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* Please note that from the start of 2014, the HPRA 
changed the way we define market surveillance 
cases and so the figures in the graph have been 
adjusted* by applying the pre-2014 definition to 
allow for comparison with 2012 and 2013 figures.
• We continued to focus our vigilance activities 
during 2018 on the areas of user reporting and 
dissemination of HPRA medical device safety 
communications. This included:
– The receipt and assessment of 2,358 medical 
device vigilance cases, similar to numbers 
received in 2017. Of the 1,067 incident reports 
notified to the HPRA, 23% came from users of 
medical devices. Manufacturers accounted for 
55% of all reports received in 2018 while 33% 
came from other competent authorities; 
– There were 415 field safety corrective actions 
(FSCA) affecting the Irish market relating to 
medical devices including 133 product removals 
conducted in Ireland during 2018; 
– The HPRA also issued 74 national competent 
authority reports, 13 notified body forms and 11 
vigilance enquiry forms;
– The HPRA issued 39 safety notices in relation to 
medical device issues and 26 direct to healthcare 
professional communications; 
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– Implants, surgical devices, orthopaedic devices 
and infusion devices accounted for 53% of the 
total vigilance reports. Reports continue to be 
received relating to diagnostic imaging and 
radiotherapy devices. During the year, we also 
continued development work on signal detection 
of medical device issues;
– In the second half of 2018, we received a 
significant number of reports from members of 
the public in relation to urogynaecological mesh 
implant devices.
• As part of its market surveillance activities, the 
HPRA undertakes proactive and ‘for-cause’ audits 
of manufacturers, notified bodies and authorised 
representatives with the objective of monitoring 
compliance of devices emanating from Irish 
based organisations. During 2018, 15 audits were 
performed at notified bodies, medical device 
manufacturers and authorised representative 
facilities, of which:
– six were for cause audits, one of which was in the 
US;
– nine were based on proactive market surveillance 
projects and notified body surveillance/
assessment.
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Legislation and Regulation
• The two new European Regulations on medical 
devices will become fully applicable in 2020. We 
continued our work during 2018 to help ensure 
an effective and timely implementation of these 
EU Device Regulations (EUDR) at national and 
European level. This included:
– Formalising a HPRA programme plan for 
development of appropriate resources, process 
and systems to meet our obligations under the 
new EUDR;
– Preparing detailed information relating to the new 
requirements with respect to the need for national 
legislation, the timelines and impact on existing 
national legislation;
– Contributing to the European Commission’s 
development of the secondary legislation 
involving implementing and delegating acts; 
– Participating in the new EU Medical Device 
Coordination Group (MDCG). Chaired by the 
EU Commission, this group is responsible for 
the overall coordination and governance of the 
regulatory system;
– Participating in the EU steering group for 
development of the new European database 
(MDR EUDAMED) envisaged under the new 
Regulations. The HPRA also participated 
in a number of the associated technical 
working groups on certificate and registration, 
unique device identification (UDI) and clinical 
aspects with a view to developing the system 
requirements and functional specifications. 
 We continued to engage with the Department of 
Health throughout 2018 on policy and legislative 
issues arising from implementation of the new EU 
Regulations. At national level, we further developed 
our national fee-based funding model for medical 
devices to recover costs associated with our 
medical device activities. The model was revised 
in 2018 to streamline and address some of the 
comments and feedback received in response to 
the model’s original introduction in 2017.
• The HPRA continues to play a significant role in 
the development of EU regulatory systems and 
mechanisms to promote coordination, cooperation 
and consistency. In 2018, this included:
– Re-election to the Executive Group of the 
Competent Authorities for Medical Devices 
(CAMD) network. This group has successfully 
worked in partnership with the EU Commission 
over the last number of years to develop the 
regulatory system in Europe;
– Participation in the CAMD’s Implementation Task 
Force (ITF) and Transition Subgroup (TSG) which 
aim to improve coordination and consistency of 
implementation of the new EU Regulations;
– Continuing to lead the work of the clinical 
investigation and evaluation working group 
(CIEWG), acting as the co-chair along with the EU 
Commission. 
• We continued to participate actively in initiatives 
to promote regulatory convergence and 
harmonisation of medical devices globally through 
the International Medical Device Regulators Forum 
(IMDRF). This involved:
– Participation in the IMDRF Management 
Committee as part of the European delegation 
(along with the EU Commission, France and 
Germany); 
– Continuing to act as the IMDRF secretariat for 
the National Competent Authority Report (NCAR) 
Exchange programme. We also participated in 
a number of different IMDRF working groups 
including the group on regulated product 
submissions (RPS) and the Medical Device Single 
Audit Programme (MDSAP);
– Contributing to discussions and development 
of the Good Regulatory Review Practice (GRRP) 
working group which is now developing a scheme 
similar to MDSAP but that relates to product 
reviews. We will place further priority on this work 
in 2019;
– Contributing to briefings for the EU Commission 
for the purposes of the MDSAP Regulatory 
Authority Committee discussions and 
encouraging discussions at EU level to further 
Europe’s future engagement in the programme.
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Stakeholders and Partners
• We continued to work on developing our 
stakeholder engagement and communication with 
medical devices stakeholders throughout 2018. 
This included the promotion of direct reporting 
of incidents and medical devices issues by 
device users and members of the public. We also 
continued our engagement with health services and 
healthcare professionals to encourage reporting 
and raise awareness of the roles and activities of 
the HPRA. We again promoted the adoption and 
communication of the HPRA step-by-step guide 
to user reporting which is targeted at healthcare 
providers. 
• The HPRA undertook a number of communication 
initiatives to raise awareness of the impact and 
requirements being introduced as a result of the 
new EUDR. During 2018, we:
– Held an information day on the new Regulations 
in Galway. The event was attended by around 250 
participants; 
– Continued to update the HPRA website to 
provide information and guidance regarding 
EUDR; 
– Provided briefings, advice and workshops on 
the new Regulations to a range of different 
stakeholders including notified bodies and 
distributors. 
• Throughout the year, we engaged in ongoing 
strategic, operational and communication 
initiatives on a bilateral and multilateral basis 
with European and international authorities, and 
the EU Commission. We also further developed 
our bilateral partnerships with a number of 
those authorities. In addition, we participated in 
operational and strategic discussions on developing 
cooperation between the CAMD and the Heads of 
Medicines Agencies (HMA) networks.
• The HPRA continues to deliver a programme of 
presentations and talks to a range of external 
stakeholders. A full list of all presentations related 
to the regulation of medical devices that were 
delivered during 2018 is provided in Appendix 2.
Medical Devices: Key Figures
Year 2016 2017 2018
Lead Competent Authority role 
on specific vigilance issues
98 89 74
NCARs and vigilance related 
communications 
116 96 111
Vigilance cases received/
opened
2,242 2,339 2,358
Field safety notices uploaded 476 519 475
Medical device safety notices 46 44 39
Medical device targeted 
healthcare professional 
communications
33 23 37
NCARs managed as IMDRF 
NCAR secretariat
18 8 8
COEN reports (market 
surveillance and vigilance) to 
EU network
45 44 38
Medical device information 
notices
0 5 2
Market surveillance cases 
(unadjusted)
335 411 353
Notifications relating to notified 
body certificates
959 844 1,174
Classification requests 35 51 37
Compassionate use 
applications
5 5 8
Medical device free sale 
certificates
2,122 2,371 2,581
Medical device queries 
received
477 496 547
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Authorisation and Registration
The authorisation of blood establishments, tissue 
establishments and organ procurement organisations 
/ transplantation centres permits those facilities to 
carry out specified activities. The total number of 
authorisations in place at year end for the past five 
years is presented by category in the accompanying 
table. 
Number of 
Authorisations
2014 2015 2016 2017 2018
Blood 
establishments
4 3 3 3 3
Tissue 
establishments
24 24 25 25 26
Organ 
procurement/
transplantation 
0 4 4 4 4
Safety and Quality
• Following collaboration with the National 
Haemovigilance Office (NHO), we submitted an 
annual report of serious adverse reactions and 
events to the EU Commission during 2018. The 
report reflected information received by the NHO 
in 2017 and included information on 59 serious 
adverse reactions and 139 serious adverse events 
which met the mandatory legislative reporting 
requirements. 
• We also submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2018. The 
report reflected information received in 2017 and 
consisted of some 59 reports, 49 of which met the 
legislative reporting requirements, including seven 
serious adverse reactions and 42 serious adverse 
events.
• The Joint Action on Vigilance and Inspection for the 
Safety of Transfusion, Assisted Reproduction and 
Transplantation (VISTART) programme concluded in 
2018. As part of the HPRA’s contribution to VISTART 
activities, we led Work Package 9 which involved 
a voluntary programme of inter-member state 
auditing of inspection systems. Consequently, we 
carried out pilot audits using tools developed under 
this work package. 
 
Blood, Tissues 
and Organs
The HPRA is responsible for monitoring 
the safety and quality of blood and 
blood components, and of tissues and 
cells. Along with the HSE, we are joint 
Competent Authority for organs intended 
for transplantation.
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Further updates to the common approach for 
defining reportable serious adverse reactions and 
events and other vigilance activities in Europe are 
being continued under the Expert Sub-Group on 
Vigilance for Blood Tissues and Cells (VES), in which 
the HPRA is actively participating. 
• We continued to liaise with the HSE lead and 
colleagues from Organ Donation and Transplant 
Ireland (ODTI) in relation to our respective roles 
under EU and national legislation on the Quality 
and Safety of Human Organs intended for 
Transplantation. During the past year, this included:
– The exchange of relevant information on serious 
adverse reactions and events. In 2018, the HPRA 
received 20 reports of serious adverse reactions 
and events associated with organ donation / 
transplantation;
– Updates to the serious adverse reaction / event 
report form;
– Contribution to the review of the framework for 
quality and safety. 
• We inspect relevant establishments, organisations 
and centres to monitor compliance with applicable 
national and EU legislation and guidelines on 
the quality and safety of blood, blood products, 
tissues and cells, and human organs intended for 
transplantation. Our inspection programme in 2018 
included:
– 9 tissue establishment inspections of which two 
were non-routine; 
– 7 routine inspections of blood establishments; 
and 
– 3 routine inspections of organ establishments.
Legislation and Regulation
• As part of our ongoing contribution to the review 
of relevant legislation, we provided feedback to the 
Department of Health on draft statutory instruments 
(SIs) for transposition of EU Directives on coding 
and import of human tissues and cells. 
• In relation to assisted human reproduction, we 
engaged with the Department of Health on 
development of related legislation. We also 
engaged in respect of the commencement of parts 
2 and 4 of the Children and Family Relationships 
Act 2015.
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Veterinary  
Medicines
Our role is to grant licences for veterinary 
medicines subject to a review of their safety, 
quality and effectiveness. We continuously 
monitor the use of the products concerned in 
animals once they become available on  
the market in addition to authorising  
clinical field trials and inspecting /  
licensing manufacturing sites.
Authorisation and Registration
• There are a number of procedures through which a 
veterinary medicine can be authorised by the HPRA. 
These include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). The following applications were 
issued by the HPRA during 2018: 
– 11 new national applications; 
– 53 new applications made under the DCP; 
– 6 new applications made under the MRP. 
 We acted as reference (lead) Member State for the 
assessment of three of the MRPs and ten of the 
DCPs. We also led a further ten applications as RMS 
under the repeat use procedure.
 The centralised route administered by the EMA is 
another mechanism whereby veterinary medicines 
can be authorised for supply in Ireland. In 2018, 
HPRA experts acted as rapporteur or co-rapporteur 
in respect of three new veterinary medicines. An 
additional 13 new medicine applications were 
issued through the centralised route where HPRA 
experts played a supporting role in the overall 
assessments.
 By end of year, there was a record total of some 
1,800 veterinary medicines authorised by the HPRA.
• During 2018, HPRA experts acted as co-ordinator 
for three requests under the EMA scientific advice 
procedure.
• With regards to Brexit planning and preparation 
(see also pages 11 to 13), we focused on the HPRA’s 
key strategic aim of protecting the availability of 
veterinary medicines on the Irish market while also 
optimising our role within the European regulatory 
network. During the past year, this included:
– Changes to transfer procedure made to mitigate 
against Brexit related shortages. There was a total 
of 180 transfers of the RMS role to the HPRA;
– Engagement with industry to identify potentially 
vulnerable products;
– Recruitment and training of additional staff in 
response to anticipated increase in workload;
– Agreement with the UK’s Veterinary Medicines 
Directorate for a work-sharing arrangement post 
Brexit. 
• Medicine shortages continue to be a challenge for 
many veterinary practitioners tasked with treating 
many different species and conditions. Problems of 
non-availability can arise from a number of issues 
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and different solutions are needed depending on 
the issues involved. In 2018:
– We conducted planned quarterly reviews of AR18 
and AR16 lists which provide details of veterinary 
medicines that have been granted special import 
licences by the Department of Agriculture, Food 
and the Marine. The HPRA strategy is to review 
the lists to identify required medicines and 
to encourage an applicant to seek a standard 
marketing authorisation where practicable.   
– Carried out gap analysis and prioritised 
applications linked to shortages.  
– Meetings were held with the Department of 
Agriculture, Food and the Marine to discuss 
shortages related issues including the need to 
develop an inter-departmental process in respect 
of potential shortages arising from Brexit. 
– Communicated and met with applicants regarding 
transfer of RMS to Ireland. We also revised the 
relevant procedure and established a register of 
products for transfer.
– We worked closely with EU competent authorities 
to enable the use of common packs. 
Authorisation and registration: Key figures
Year 2016 2017 2018
Classification enquiries 16 11 26
Clinical trials 1 2 10
New centralised as (co-)
rapporteur 11 16 3
New MR/DCP as RMS 14 30 34
New MR/DCP as CMS 78 44 57
New homeopathic applications 0 3 0
New national applications 8 8 11
Renewals, national and MR 100 108 148
Variations, national and MR 1,341 1,366 1,820
Manufacturers of veterinary 
medicines 24 20 23
Export certificates 155 111 109 
Safety and Quality
• The operation of a national pharmacovigilance 
system for veterinary medicines is dependent 
on the submission of reports by veterinarians, 
pharmacists, licensed merchants and others 
involved in dispensing or using the medicines 
concerned. These reports may be submitted either 
directly to the HPRA or to the companies marketing 
the medicines. The companies, in turn, must relay 
the data to the HPRA. 
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• Over the course of 2018, we received 394 national 
reports of suspected adverse events to veterinary 
medicines with the vast majority of reports, as 
in previous years, received from pharmaceutical 
companies. 
• We processed 1,233 periodic safety update reports 
(PSURs) which incorporated the assessment of 
individual medicines on the market in Ireland as 
well as a work-sharing initiative where we led, 
or contributed to, the assessment of a class of 
veterinary medicines for the European Union.  
• Containment of the development of antimicrobial 
resistance (AMR) is essential for public and animal 
health. Our work in this area includes the collection 
of annual information on the sale of veterinary 
antibiotics from each marketing authorisation 
holder. This information, which is included in the 
European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), is important as it allows us 
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to benchmark our usage rate against those of our 
European neighbours and to follow any developing 
trends. The data show that due to a variety of 
factors there are significant fluctuations in sales 
annually and, consequently, that a clear trend is not 
identifiable.
Veterinary antibiotic 
use 2013 2014 2015 2016 2017
Tonnes sold 99.1 89.4 96.9 103.4 99.7
 
 Additionally in 2018, we collaborated with the 
Department of Agriculture, Food and the Marine 
to support the development of a database for 
antimicrobial consumption as per ‘Ireland’s National 
Action Plan on Antimicrobial Resistance 2017-2020’. 
• The analytical testing of products is a key 
component of the HPRA’s risk based sampling and 
analysis programme. Five samples of veterinary 
medicines were taken under the programme and 
all were subjected to laboratory testing. While the 
majority of the samples tested were compliant 
with their specifications, a number of issues, such 
as crumbling of tablets, were noted. Appropriate 
follow-up actions were taken as necessary.
• We investigate, on a risk basis, reports of suspected 
quality defects in medicines and active substances, 
and co-ordinate subsequent recalls from the Irish 
market where necessary. There were 125 quality 
defects pertaining to medicines for veterinary 
use reported or identified. The risk classifications 
that were assigned, along with the corresponding 
figures for the previous two years, are outlined in 
the accompanying table.          
Year 2016 2017 2018
Critical quality defects 7 5 26
Major quality defects 12 13 43
Minor quality defects 22 30 56
Number of reports not justified 0 0 0
Total Number Quality Defects 41 48 125
 Companies (50%), including manufacturers, 
distributors and/or authorisation holders, and other 
competent authorities (47%) were the primary 
sources of reports received.  
 In certain cases, in order to protect animal and / or 
public health, it is deemed necessary to withdraw, 
or recall, a veterinary medicine from the Irish 
market. Six recalls of medicines occurred which was 
one less than in 2017. Of these, three were recalled 
due to a lack of sterility assurance.
• Our inspections and audits programme focuses 
on ensuring industry compliance with relevant 
standards and legislation. In 2018, there were: 
– 12 good manufacturing practice (GMP) 
inspections of sites that manufacture / test 
veterinary medicines;
– 2 pharmacovigilance inspections.
Legislation and Regulation
• We continued to engage with the Department of 
Agriculture, Food and the Marine in respect of the 
proposed new EU veterinary medicines legislation. 
Meetings were held to review the proposals and 
we presented feedback to the Department. We 
continued to consider and plan for the potential 
impact of the legislation on HPRA procedures 
and published a broader impact analysis in the 
Veterinary Journal publication. 
 We note that discussions in the European Council 
and Parliament on the new legislation reached a 
successful conclusion by year end and work can 
now begin on the planning for its implementation. 
• We completed a report on the potential impact of 
the ongoing judicial review proceedings contending 
that the labelling and packaging of veterinary 
medicines should be in both the Irish and English 
languages.
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Stakeholders and Partners
• As part of our ongoing stakeholder engagement, in 
2018:
– We held a Veterinary Medicines Information 
Day to inform stakeholders of ongoing issues 
and recent developments. In addition to HPRA 
updates, presentations were also delivered by the 
Department of Agriculture, Food and the Marine 
and the UK’s Veterinary Medicines Directorate. 
Among the topics discussed were:   
- The new EU legislative framework for veterinary 
medicinal products;
- Brexit developments and the preparations 
undertaken by the HPRA;
- Information on GMP and pharmacovigilance;
- HPRA performance data.
– In respect of support for innovation, we were 
appointed as rapporteur for three veterinary 
vaccines in addition to taking over the RMS 
role for a number of vaccine products from the 
UK. We also undertook a peer review of a stem 
cell product. Additionally, we held a number of 
meetings with stakeholders during the year as 
part of our review and audit of the current level of 
national regulatory and scientific advice provision 
at each stage of product development.
– As part of our commitment to enhance our 
stakeholder communication on safety issues, we 
developed and published a number of safety 
notices on our website in relation to product 
recalls and changes to withdrawal periods, and 
specific topics including diethanolamine and 
enrofloxacin.  
• Throughout 2018, we continued our involvement 
across the EU regulatory network which includes 
active participation at the EMA and the HMA.  
• As in recent years, we delivered a programme 
of presentations to veterinarian students and 
veterinary nursing students on the role of the HPRA 
and the promotion of veterinary pharmacovigilance. 
We also presented at a number of industry 
stakeholder events. A full list of all presentations 
delivered during 2018 is provided in Appendix 2. 
 
• Our Medicinal Products Newsletter provides 
updates for those working in the veterinary 
medicines sector on Irish and European legislation, 
new / revised HPRA regulatory publications and 
stakeholder events such as information days. Three 
editions were published on our website in 2018 and 
are available to download from the ‘Publications’ 
section.
 We also contributed a number of articles to the 
Veterinary Ireland Journal and the It’s Your Field 
publication. Details are included in Appendix 3. 
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Scientific Animal  
Protection
The HPRA is the competent authority in 
Ireland responsible for the implementation 
of EU legislation (Directive 2010/63/EU) for 
the protection of animals used for scientific 
purposes.
Authorisation and Registration
• The HPRA carries out evaluations of applications 
for the authorisation of research establishments and 
projects in addition to evaluating applications from 
individuals to allow them to manage projects or to 
conduct procedures or euthanasia of animals. 
 As shown in the accompanying table, there 
was an increase in the total number of projects 
authorised in 2018. In addition to the new individual 
authorisations issued during the year, there were 
also 152 renewals of individual authorisations. 
Please note that the higher level of individual 
authorisations during 2014 was due to the legal 
requirement for existing establishment personnel to 
apply for individual authorisations, which are valid 
for five years, before the end of 2014. 
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• In November, we published the fifth annual 
statistical report on the use of animals for scientific 
purposes in Ireland. The HPRA is required to collect 
and make publicly available, on an annual basis, 
statistical information on the use of animals in 
procedures, including information on the actual 
severity of the procedures.
Authorisation and registration – Key 2018 figures:
Individual authorisations 308
Individual renewals 152
Project authorisation 143
Individual amendments 45
Project amendments 253
Establishment renewals 3
Safety and Quality
• During 2018, there were 23 inspections 
completed to monitor animal welfare standards 
and compliance with legislation, of which 39% 
were unannounced. This total incorporated one 
establishment authorisation inspection and 22 
compliance inspections.
 Of the 54 non-compliances recorded under 
the annual inspection programme, 37% were 
self-reported to the HPRA by personnel at the 
authorised establishment with the remainder 
detected on inspection. Non-compliances are 
categorised as Type 1, Type 2 and Type 3 with Type 
1 being the most serious and Type 3 being more 
minor in nature. In 2018, 20% of non-compliances 
were Type 1, 61% were Type 2 and 19% were Type 
3. The most common non-compliances recorded 
related to (i) breaches of project authorisations, (ii) 
failure to carry out routine health checks and (iii) 
issues with supply of food or water to animals.    
Stakeholders and Partners
• In 2018, we published and disseminated four 
‘Regulatory Updates’ to provide stakeholders 
with the latest news and guidance from the HPRA 
including information on best practices in respect of 
the 3Rs and compliance with the legislation.
• We delivered a number of Laboratory Animal 
Science and Training (LAST) lectures in relation to 
the legislative and regulatory aspects of scientific 
animal protection. In April, we delivered a lecture 
at the British Society of Animal Science Annual 
Conference 2018, in relation to the application of 
the legislative requirements in agricultural research. 
In October, we delivered a lecture at a workshop 
held by the National Committee for the Protection 
of Animals used in Science regarding the HPRA’s 
evaluation of the 3Rs in project applications.  
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Controlled 
Drugs and 
Precursor 
Chemicals
Authorisation and Registration
• Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority 
while the HPRA handles the administrative aspects 
of the application and licensing process. Licensing 
activity consists primarily of export and import 
licences, and letters of no objection. Data for the 
past five years are outlined in the accompanying 
graph.
• The HPRA is the licensing authority for precursor 
chemicals. These are subject to different licensing 
requirements, dependant on specific categories. 
The following table shows the licensing activity 
since 2014.
Precursor Chemicals 
Licensing Activity 
2014 2015 2016 2017 2018
Total 46 32 16 23 23
Legislation and Regulation
• Throughout 2018, the HPRA provided support to 
the Department of Health in their preparations to 
establish the Medical Cannabis Access Programme. 
Clinical guidance, developed by an Expert 
Reference Group established by the Minister, is 
available from the Department’s website and it is 
anticipated that the legislation required to underpin 
the programme for Irish patients will be published 
during 2019. This will permit consultants on the 
specialist medical register to initiate treatment with 
specified cannabis based products for patients with 
any of three specified conditions: 
- Spasticity associated with multiple sclerosis 
resistant to all standard therapies and 
interventions; 
- Intractable nausea and vomiting associated with 
chemotherapy, despite the use of standard anti-
emetic regimes; 
- Severe, refractory epilepsy that has failed to 
respond to standard anticonvulsant medications. 
The products for use via the Medical Cannabis Access 
Programme are not considered to be medicines. 
Consequently, a separate framework for their 
importation, supply, prescribing, dispensing and 
possession is required under the Misuse of Drugs 
legislation. Only cannabis based products for medical 
use that meet criteria set out in the associated 
legislation will be permitted under the Medical 
Cannabis Access Programme. Further information will 
be available on the Department of Health website 
during 2019. 
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Cosmetic Products
The role of the HPRA is to regulate the manufacture, 
sale and supply of cosmetic products in Ireland.  
We identify and address cosmetic product quality 
and safety issues, in conjunction with the HSE,  
so that a cosmetic product will not compromise  
the health and safety of the consumer or  
the person applying the product. 
Authorisation and Registration
• We issued 193 cosmetics free sale certificates 
which were requested by companies intending to 
export products to non-European Economic Area 
countries. 
Safety and Quality
• As part of proactive market surveillance 
activities, we conducted five inspections of 
cosmetic distributors and two inspections of 
cosmetics manufacturers to assess compliance 
with the Cosmetics Regulation. Distributors 
and manufacturers were informed of any non-
compliances identified and requested to implement 
corrective actions.
• Our reactive market surveillance includes 
investigation of quality-related complaints 
(compliance cases), reports of adverse events 
relating to the use of cosmetics (vigilance cases) 
and serious risk alerts received from other countries 
(RAPEX). There were 379 reactive surveillance cases 
initiated which is a 21.5% increase on 2017.
Stakeholders and Partners
• In May, we were invited to present at the Irish 
Cosmetics, Detergent and Allied Products 
Association (ICDA) workshop: Potential Regulatory 
Impact of Brexit for Cosmetic and Detergent 
Companies. The workshop was attended by Irish 
cosmetics and detergent manufacturers and also by 
UK companies intending to set up their designated 
Responsible Person in Ireland. 
• We hosted an information stand at the Professional 
Beauty Show held in the RDS, Dublin, in October. 
Manufacturers and distributors of cosmetic products 
participated in this trade show. We provided 
relevant information on their responsibilities under 
the Cosmetics Regulation and distributed the HPRA 
cosmetic products information pack and leaflet on 
selling cosmetic products in Ireland to stakeholders 
as additional information.
 This show was also attended by a number of 
consumers and students who we informed of the 
risks associated with buying cosmetic products 
online and counterfeit products. We included 
a display at our stand comparing a counterfeit 
cosmetic product with the genuine product to 
highlight the features for which to be vigilant when 
purchasing cosmetic products.
• In December, we launched a media information 
campaign to raise awareness amongst consumers of 
the dangers presented by counterfeit cosmetics in 
the run up to the Christmas period. The information 
was published by both print and online media 
and we participated in a number of national and 
regional radio interviews. Consumers were informed 
of how to spot a counterfeit cosmetic and of the 
risks these products can pose.
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Other  
Regulatory 
Programmes
Inspections, Audits and Market 
Compliance
• The Joint Audit Programme (JAP) is a key 
element of the quality system adopted by good 
manufacturing practice (GMP) inspectorates in 
Europe and aims to ensure consistency of GMP 
inspection standards and a harmonised approach 
throughout Europe. In 2018, the HPRA participated 
in the JAP evaluation of the GMP compliance 
programme of another member state.
• In relation to the US/EU mutual recognition 
agreement (MRA) on GMP inspections for human 
medicines, the US FDA had, in 2017, been an 
observer of the JAP audit of the HPRA’s GMP 
inspectorate as part of its review of the equivalency 
of HPRA systems. Following the successful 
close out of that audit, a detailed data package 
was prepared and presented to the FDA for its 
consideration as part of competency assessment. 
The FDA subsequently confirmed that the HPRA 
has the capability, capacity and procedures to carry 
out GMP inspections at an equivalent level. As a 
result, Ireland was included on the list of recognised 
member states under the MRA on 1 June 2018 and 
from that point forward the FDA can rely on HPRA 
inspections of manufacturers in place of conducting 
its own inspections.
• Other EU contributions included participation in / 
leading on 
– the drafting group tasked with revision of EU 
GMP Guide Annex 1 on the manufacture of sterile 
medicinal products;
– the drafting group for the new EU GMP Guide 
Annex 21 on importation;
– the development of a new risk assessment tool 
for the selection of medicinal products and active 
substances for surveillance testing; 
– a new risk-based tool to support inspection and 
surveillance relating to heparin manufacturers and 
their related products; and 
– the development of a communication tool-kit for 
the Official Medicines Control Laboratory (OMCL) 
Network. 
 
Innovation Support
• The HPRA continues to focus on supporting 
innovation as one of our five strategic goals. This 
reflects our role not just to protect but also to 
enhance public and animal health. Our supports for 
innovation aim to facilitate safe and timely access 
to innovative health products and to increase and 
improve treatment options for patients. They also 
benefit the HPRA by helping to inform our future 
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development and allowing us to identify novel 
product types and technologies that require new 
or adapted regulatory science approaches. Our 
actions to support innovation in 2018 included the 
following:
– The HPRA’s Innovation Office continues to 
offer regulatory support and advice to anyone 
developing an innovative health product 
or technology. Over 60% of the queries to 
Innovation Office originate from academia or 
small and medium enterprises who may have 
limited access to specialist regulatory advice. 
Medical devices was the most frequent area 
addressed through Innovation Office queries 
followed closely by medicines.
– Having previously established a national horizon 
scanning process, in 2018 the HPRA focussed 
on supporting the development of similar 
processes on a European and international level. 
Horizon scanning is intended to identify novel 
health products at an early stage and inform 
the development of appropriate regulatory 
tools and approaches to ensure the effective 
regulation of such products and thereby facilitate 
patient access. We have taken a lead role in 
the development of a coordinated approach to 
horizon scanning within the European Innovation 
Network culminating in the presentation of an 
agreed proposal to the HMA in November 2018. 
The HPRA has also acted as overall project lead 
for the innovation project among members of the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA). One of the three work-
streams, which relates to leveraging the outcomes 
of horizon scanning, is jointly led by the HPRA 
and the EMA.
– Our classification process continues to offer 
advice to stakeholders on the borderline between 
different regulatory frameworks including 
medicines, medical devices, cosmetics and 
other products. 2018 saw the implementation 
of an integrated medicines and medical devices 
classification system designed to optimise the 
decision-making process. The implementation 
of this approach also reflects the ever increasing 
level of convergence between these two areas 
and it is also timely given the classification-related 
changes introduced by the new medical devices 
regulation.
– The HPRA was part of a consortium of European 
medicines regulatory agencies who successfully 
applied to the European Commission for a 
Horizon 2020 funded coordination and support 
action. This project entitled ‘Strengthening 
regulatory sciences and supporting regulatory 
scientific advice’ (STARS) will begin in January 
2019 and will seek to support academic-
led health product innovation by increasing 
regulatory knowledge and awareness.
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Improving the 
Management of 
Shortages
Establishment of a medicine 
shortages framework
Medicine shortages are increasingly prevalent 
globally, and Ireland, like all countries, has 
the potential to be affected. In order to 
address this at a national level, the HPRA 
created a new internal function to co-ordinate 
the management of shortages of human 
medicines. The HPRA’s medicines shortages 
team works closely with various stakeholders 
who have fully committed to working together 
to address this important area in the interests 
of patients. 
Multi-stakeholder collaboration
2018 saw the establishment of a national 
framework outlining a multi-stakeholder 
approach to the management of medicine 
shortages and the reduction of the impact 
they can have. Shortages can effect patients 
in particular and the multi-stakeholder 
approach places the patient right at the 
centre so that their needs underpin all 
planning and mitigating actions. The 
development of the framework involved 
the collaborative participation of groups 
representing key stakeholders in the supply 
and use of medicines:
• Government / State agencies: Department 
of Health, Health Products Regulatory 
Authority, Health Service Executive
• Patients: Irish Platform for Patient 
Organisations, Science and Industry 
(IPPOSI)
• Healthcare professionals: Irish Pharmacy 
Union, Hospital Pharmacists Association of 
Ireland, Irish Medication Safety Network, 
Irish College of General Practitioners
• Manufacturers / Distributors: Irish 
Pharmaceutical Healthcare Association, 
Medicines for Ireland, Pharmaceutical 
Distributors Federation, Association of Irish 
Pharmaceutical Parallel Distributors
The consultation process culminated in a 
stakeholder workshop hosted by the HPRA in 
July. The framework went live in September 
and has resulted in a co-ordinated national 
response to the management of medicine 
shortages. The HPRA has created a dedicated 
section on its website to provide information 
on medicines which are in short supply, and 
their anticipated return to the market. This 
is regularly updated as new information 
becomes available and a weekly update is 
sent to subscribers to the HPRA website.
The number of shortage notifications 
received by the HPRA from various sources, 
including industry, patients and healthcare 
professionals, has increased since September, 
indicating stakeholders’ willingness to engage 
in the framework. The same collaborative 
engagement has also ensured that no patient 
has gone without treatment as a result of a 
shortage. 
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International influence
Whilst the primary focus for the HPRA’s 
shortages function in 2018 was on the 
establishment of the national approach to co-
ordinate the management of shortages, the 
HPRA has also been involved internationally 
in shaping the development of a European-
wide response to medicine shortages. The 
HPRA is an active participant in the HMA/
EMA Task Force on Availability of Authorised 
Medicines and presented at a two-day 
European stakeholder workshop organised 
by this group. The Irish approach to the 
management of medicines shortages has also 
been referenced in publications such as the 
British Medical Journal.
Focus for next year
The focus in 2019 will be on further 
developing the shortages framework and 
to develop and implement preventative 
strategies to reduce the likelihood of 
shortages occurring in the first instance. 
In many cases, these will be aimed at the 
underlying causes of shortages to ensure that 
shortage prevention is actively considered 
as part of the life cycle management of the 
medicine.
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Adrenaline auto-injectors (AAIs) – A shortages case study
What are AAIs? 
Life-saving medicines that people carry with them in case there is an emergency, such as a potentially life-
threatening allergic reaction to stings or certain foods (e.g. nuts). 
What was the issue?
A shortage of one particular brand led to increased demand for other AAIs, which coincided with the seasonal 
increase in demand for all AAIs linked to the seasonal vaccination and back-to-school periods. This led to supply 
constraints for AAIs in the second half of 2018.
What was the benefit of the multi-stakeholder framework?
1. The HPRA, in collaboration with the other AAI suppliers and healthcare professionals, were able to respond 
quickly and establish the potential gap in supply as soon as the potential shortage was identified. This allowed 
a number of actions to be taken prior to the seasonal increase in demand.
2. Alternative AAI suppliers were advised of the anticipated increased demand for their products in advance 
so that they could increase production and supply to Ireland to fill the gap left by the shortage. This 
communication continued during the period of supply constraints to ensure mitigation of the shortage.
3. The HPRA liaised with the pharmacy regulator, hospital pharmacy medication safety networks and the 
community pharmacy representative body to provide information on the supply issues so that appropriate 
guidance and information could be disseminated to pharmacists to ensure a pragmatic response to the 
shortage.
4. The HPRA maintained regular communication with specialist prescribers who provided clarification to 
colleagues on appropriate prescribing of AAI strengths.
5. As some patients may have received an alternative AAI that they may have been previously unfamiliar with, 
communications highlighted that patients and their carers should become familiar with the new device and 
that pharmacists could provide advice in this regard at the point of dispensing. 
6. The shortages section of the HPRA website was updated regularly with information on the supply and became 
a ‘go-to’ site for information to patients and healthcare professionals.
Was Ireland the only country impacted?
The supply constraints were a global issue that impacted many countries, including the USA and the UK. Whilst 
the supply situation in Ireland was challenging, the actions taken ensured that a suitable AAI was available to 
dispense to patients at all times which is in contrast to the situation observed in other countries. 
Outreach and 
Engagement
The HPRA is committed to a strategic focus 
on outreach and engagement with key 
partners and stakeholders so as to enhance 
and maximise the effectiveness of the 
regulatory system. 
• In our outreach activities to support innovation 
developments in Ireland: 
– The HPRA continued to meet and interact with a 
number of other state agencies and organisations 
who seek to support innovation in Ireland 
including the IDA, Enterprise Ireland, Health 
Innovation Hub Ireland, Knowledge Transfer 
Ireland and a number of third level institutions. 
We also met with individuals and organisations 
who are seeking to develop innovative health 
products and technologies to provide guidance 
on the regulatory requirements that will apply to 
their products. 
– The HPRA participated in a number of events 
around Ireland to promote our supports for 
innovation. We presented at an Innovation in 
Medtech event organised by the Tyndall National 
Institute in Cork and a symposium organised by 
the Research Quality Association on innovation 
for health products. The HPRA attended the 
Spark Summit organised by the National Doctors 
Training and Planning section of the HSE, which 
was held in RCSI in October. We also presented 
and exhibited at the Taking Care of Business 
event organised by the Department of Business, 
Enterprise and Innovation in Limerick.  
– The HPRA continues to contribute to education 
programmes at both undergraduate and 
postgraduate levels. As part of our review of 
our contribution to such programmes which 
seeks to explore the use of online learning tools, 
we worked with the Affiliation for Pharmacy 
Practice Experiential Learning (APPEL) to 
develop on online training module for 4th year 
pharmacy students which provided an overview 
of medicines regulation and discussed the use 
exempt medicinal products. We also provided 
training placements to two 4th year pharmacy 
students as part of the new five-year integrated 
pharmacist training programme.
• Stakeholder communications and engagement:
– In October, we launched our new public 
information campaign: Zero Gains. The campaign 
is focused on building awareness of the many and 
often serious side effects associated with the non-
medical use of anabolic steroids. See page 48 for 
more details.
– The HPRA’s first ever national information 
campaign was launched in September 2016. 
The campaign, which incorporated radio, digital 
and print advertising, was repeated in 2017 and 
again between September and October 2018. 
The focus of the HPRA adverts was to highlight 
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the importance of the safe use of medicines as 
well as medication adherence in general. Our key 
message to members of the public is to take care 
when taking medication and specifically to be 
aware of and read the information and directions 
for use that come with every medicine. Our 2018 
media plan focussed particularly on national and 
regional radio stations in addition to digital online 
advertising. 
– Throughout the year, we continued our media 
communications programme to proactively 
communicate important safety messages and 
to build awareness of the role of the HPRA. We 
issued 20 press releases and website statements 
concerning safety and regulatory matters to 
ensure consumers, healthcare professionals 
and other stakeholders received timely and 
accurate information and advice. In a number 
of instances, these communications resulted in 
national and regional media interviews with a 
HPRA spokesperson. In addition, we responded 
to approximately 500 initial and follow-up queries 
from national, local and specialist media during 
the year.
– The HPRA was pleased to participate as one of a 
number of education partners working with the 
Irish Platform for Patient Organisations, Science 
& Industry (IPPOSI) to deliver a Patient Education 
Programme in the area of health innovation. 
The programme, which was specifically tailored 
for Irish patient communities, was piloted 
from September 2017 to March 2018 based 
on a ‘blended learning’ approach consisting 
of e-learning and face-to-face sessions. The 
HPRA module, which ran for five weeks, was 
focused on regulatory affairs, medicines safety 
and pharmacovigilance. Our Chief Executive 
participated in the informal programme 
graduation which took place in March. 
– The HPRA website – www.hpra.ie – is a key 
communications channel and we continuously 
monitor and analyse key visitor and usage 
statistics. Among the key findings from 2018 
were: 
- Almost 526,000 unique visitors accessed 
our website during the past twelve months 
representing a significant 67% increase 
compared to 2017. 
- There were in excess of one million visits in total 
throughout the year which is the highest annual 
number recorded for our website. 
- Of those who accessed the site, more than 50% 
were new or first time users. 
– The @TheHPRA Twitter account was 
launched in late 2016 as a tool to support our 
communications activities and direct additional 
traffic to the HPRA website. We continued to 
develop our Twitter activity during 2018 and by 
year end we had more than doubled our number 
of followers to 1,804. We tweeted 222 times 
resulting in more than 789,000 impressions. 
Among the highlights was our participation in an 
international social media campaign to promote 
the reporting of suspected side effects from 
medicines. This campaign was supported by a 
range of patient organisations and other national 
health agencies.  
– Also during 2018, we launched a corporate 
Instagram account to highlight and promote 
certain activities and events. This included the 
use of an Instagram wall during ICDRA 2018 in 
Dublin and the use of Instagram stories as a key 
component of our Zero Gains anabolic steroids 
information campaign. 
• European and international contribution: 
– Details of the extensive Brexit preparatory work 
carried out by the HPRA during 2018 are outlined 
on pages 11 to 13. 
– The HPRA hosted the 18th International 
Conference of Drug Regulatory Authorities 
(ICDRA) in collaboration with the World Health 
Organization (WHO) in Dublin from 3 to 7 
September 2018. This biennial event, which 
was opened by the Minister for Health, is the 
largest global gathering of medicines regulators 
and provides delegates with a unique forum 
to meet and discuss ways to strengthen global 
collaboration in the area of medicines’ regulation. 
The theme for ICDRA 2018 was ‘Smart Safety 
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Surveillance – A life-cycle approach to promoting 
safety of medical products’. The initial two-
days, known as Pre-ICDRA, were open to both 
regulators and industry representatives and 
attracted 350 delegates. Topics discussed 
included regulatory collaboration, certification of 
pharmaceutical products, biosimilars and medical 
devices. The remaining three days of ICDRA 
were open to regulatory authorities and attracted 
300 delegates from 83 WHO member states. 
There was a focus on a wide range of topics 
including haemovigilance, regulation of clinical 
trials and supply chain integrity. In advance of the 
conference, the HPRA team was also engaged in 
significant preparatory work in collaboration with 
the WHO. This included venue management, 
operation of the online booking process and the 
launch and updating of the official event website, 
icdra2018.ie  
– The HPRA leads the coordination of the overall 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) innovation project as well 
as co-leading on a work stream with the EMA. 
The work from this project was presented at 
DIA Europe in Basel and interim work stream 
reports were prepared and presented at the 
ICMRA Summit which took place in Washington 
in September. This was followed by further 
discussions at DIA in Japan in November. The 
final report will be presented at DIA Europe 
taking place in Vienna in February 2019.
– During the year, the HPRA was appointed as a 
member of the European Heads of Medicine 
Agencies (HMA) Management Board. Alongside 
the HMA meetings which took place in Lisbon, 
Sofia and Vienna, we also participated as part of 
the secretariat for the monthly meetings of the 
HMA Brexit Task Force. 
– We attended the quarterly EMA management 
board meetings in London. The coordination 
of Brexit related issues and the planned EMA 
relocation to Amsterdam were two items 
dominating the agenda throughout the year. 
Other ongoing issues included the new 
veterinary legislation and clinical trials regulation 
implementation.
– We continued providing technical assistance to 
the Zambia Medicines Regulatory Authority with 
our consortium partners. This included hosting 
a study visit from a ZAMRA human medicines 
assessor. A report on cost containment and 
income generating strategies was also issued to 
the Zambian agency following a short term expert 
visit by a member of the HPRA finance team.
– HPRA information seminars and training events 
provide regulatory guidance and updates to a 
range of stakeholders. The HPRA also partners 
with other regulatory organisations to co-host 
relevant sessions. During 2018, we hosted the 
following events:  
- Joint Action for Market Surveillance meetings - 
26th March, 31st May, 20th June
- Medical Devices Information Day – 23rd May
- Veterinary Information Day – 13th June
- Medical Devices Work Package Conference – 
4th and 5th September
- VISTART (Vigilance and Inspection for the 
Safety of Transfusion, Assisted Reproduction 
and Transplantation) Joint Action project - 11th 
September, 12th and 13th September
- Scientific Animal Protection 3Rs Training Day – 
4th October
- Good Clinical Practice (Compliance Information 
Day) – 23rd October
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Key outreach and engagement figures 2018 
Year 2018
Public consultations launched:
 - Proposed regulatory fees for human and veterinary medicines
 - Proposed regulatory fees for medical devices
 - Framework for multi-stakeholder approach to handling medicines shortages
3
Public consultations we responded to:
 - Included HMA, PSI, Health Information and Quality Authority, and Health Research Board 
7
Events managed by HPRA events teams 10
Freedom of information requests 32
Requests received in accordance with the Data Protection Acts 12
Parliamentary questions 46
Queries from government departments or members of the Oireachtas 71
Protected disclosures received by external persons under section 7(2) of the protected Disclosures Act, of 
which investigation is: 
 - Concluded
 - Ongoing
5
1
Protected disclosures from HPRA staff members 0
Complaints 2
Customer service queries 3,454
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Dangers of anabolic 
steroids highlighted 
by new HPRA  
‘Zero Gains’ 
campaign
In October, the HPRA launched a new month 
long public information campaign to raise 
awareness of the potentially serious side 
effects and health risks of using unprescribed 
anabolic steroids. 
The ‘Zero Gains’ campaign, which was 
launched by the Minister for Health, Simon 
Harris T.D., targets young Irish men and was 
developed in light of growing evidence of 
an increased use of anabolic steroids for 
body enhancement as well as new research 
showing a significant lack of awareness of 
the serious health complications posed by 
these products. The potential physical effects 
include heart failure, liver issues, kidney 
damage, and infertility as well as acne and 
hair loss. The psychological and emotional 
impacts include mood swings and aggression 
or ‘roid rage’ leading to possible depression. 
In addition, there are the very real risks 
associated with injecting anabolic steroids 
into the body while for younger males in 
particular, where their bodies are still growing 
and developing, there may be specific 
consequences such as stunted growth and 
premature ageing of the bones.
This national campaign, incorporating social and 
digital media in addition to outdoor and in-
gym adverts, will be repeated during 2019 and 
2020. A new website www.zerogains.ie was 
launched as part of the campaign to provide 
reliable and trustworthy information on the real 
risks of anabolic steroid use. It also provides 
practical advice to help anyone who is suffering 
from issues with use and provides details on 
how members of the public can report concerns 
about the illegal sales and supply of steroids to 
the authorities.
The sale and supply of anabolic steroids to 
the public outside of a registered pharmacy 
is illegal. As authorised prescription-only 
medicines, they are only available on foot of 
a prescription from a doctor to treat specific 
medical conditions. Growing evidence 
ranging from the increasing levels of illegal 
products detained by the HPRA each year, as 
well as needle exchange figures and a number 
of tragic deaths highlighted in the media 
in recent times, point to a growth in non-
medical use in Ireland. The HPRA, working 
in conjunction with An Garda Síochána and 
Revenue’s Customs Service, detained more 
than 650,000 dosage units of illegal anabolic 
steroids during the three years 2016 to 2018. 
New HPRA research carried out in 2018 found 
that a significant proportion of Irish people 
are unaware of the many serious side effects 
caused by anabolic steroid use. Almost half 
of Irish adults (48%) are unaware/not sure 
about the side effects of steroid use meaning 
that lack of awareness of specific health risks 
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is significant. While almost 1 out of every 
5 (19%) is aware (unprompted) that using 
anabolic steroids can cause heart problems, 
awareness levels of other known health risks 
are quite significantly lower. Only 8% of 
respondents referred to mood swings, 7% to 
aggression and just 4% to liver damage. Also 
of concern were the findings that:
• more than 1 in 4 people claim to know 
someone who has previously used 
unprescribed anabolic steroids; 
• 1 in 10 adults would consider taking 
anabolic steroids to enhance physical 
performance or gain a more muscular 
physique, rising to more than 1 in 5 of  
those aged 18-34 (22%).
The ‘Zero Gains’ campaign makes clear 
and trustworthy information on real risks of 
use available to young men through media 
platforms, imagery and language they will 
relate to. It is focused on changing attitudes 
and dispelling the myth that non-medical 
use of these products is safe and that users 
have nothing to lose by taking them. On the 
contrary, young men have a lot to lose starting 
with their health and wellbeing. Taking 
everything into account, including the range 
of physical, psychological and emotional 
damage they can cause, the HPRA campaign 
is intended to challenge the preconception 
among healthy young Irish men that they only 
stand to gain from anabolic steroid use.   
Pictured at the launch 
of the “Zero Gains” 
campaign in October 
were Minster Simon 
Harris T.D. and HPRA 
Chief Executive,  
Dr Lorraine Nolan
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Campaign Creatives
The HPRA’s visual campaign highlights the 
negative health impacts of anabolic steroids 
including mood swings and aggression (often 
referred to as roid-rage), depression, acne 
and hair loss, heart and liver issues, infertility 
and fluid retention. Further information on the 
many dangers associated with steroid use can 
be found on zerogains.ie.
Campaign Performance
• One month after the campaign launched, 
research showed that that more than 1 in 5 
of all 18 to 24 year olds in Ireland recalled 
seeing the adverts.
• There were more than 10,000 visitors to the 
zerogains.ie website by end of December. 
Of these, 57% were male with the age 
group 25-34 accounting for the most 
visitors. 70% of the users of the site visited 
using a mobile device.
• A key component of the campaign media 
plan, given the highly visual nature of 
the campaign creatives, was the use of 
Instagram stories on the hugely popular 
photo-sharing social media network. This 
element of the campaign alone delivered a 
reach of 803,173.
• Geofencing, which enables targeted mobile 
users to be presented with digital adverts 
within online apps, was also part of the 
HPRA campaign. This component of the 
media plan delivered 827,919 impressions 
and additionally delivered 3,466 click 
throughs to the zerogains.ie website. 
 
Mood swings and depression are just 
part of the profile of steroid users.
For more information and guidance visit ZeroGains.ie
Next Steps
The campaign will be repeated on a number 
of occasions during 2019. The HPRA is 
very much open to engaging with relevant 
stakeholders to ensure this critically important 
public health message reaches the intended 
audience. We will also endeavour to enhance 
our media mix and creative approach to 
ensure the campaign evolves and remains 
both fresh and relevant. 
Organisational 
Development
The HPRA is committed to having the necessary 
corporate functions, systems and supports in 
place to deliver on our public health mission. 
We must ensure that our organisational 
capabilities continue to expand and evolve in 
line with regulatory and scientific developments 
and that we adapt to other changes in our 
operating environment. 
Human Resources and Change
Our HR and Change Strategy 2016 – 2020 continued 
to provide the framework for the development of our 
internal capabilities in the HPRA. The six core themes 
identified within the strategy drive our progress with 
various initiatives delivered throughout the year. 
During the year:
• Delivery of our Management Development 
Programme (MDP) continued with the completion 
of phase one and the design and commencement 
of delivery of phase two. Our Management 
Committee members also began our Institute of 
Leadership and Management (ILM) accredited 
Leadership Development Programme (LDP) in 2018, 
sponsored by our Chief Executive.
• Our cross organisational working group continued 
the development of skills matrices for our various 
scientific roles in the HPRA. 
• Our graduate recruitment programme commenced 
officially in September 2018 with our first graduates 
joining the organisation. Recruitment for the second 
programme, due to commence in 2019, was 
conducted at the end of the year. 
• 2018 was a hugely successful year for the HPRA in 
terms of our health and wellbeing agenda. During 
the year we became the first public sector body 
to receive the KeepWell Mark accreditation while 
we were also recipients of a national HR award for 
Best Health and Wellbeing Initiative. The receipt 
of a gold Active@Work award from the Irish Heart 
Foundation was further recognition of our efforts in 
this area.  
HR&C
Strategy
2016-2020
Retention &
Engagement
Change 
Management
HR & 
Change
Organisation
Design
Talent 
Management
Career
Development
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• We strengthened our presence on social media 
and increased the focus on our employer brand 
via LinkedIn and Instagram. This included 
the development, working closely with our 
communications colleagues, of an ‘About Us’ 
recruitment video which we will use on social media 
to support other efforts to grow our brand as an 
employer of choice.
• Resourcing plans were developed to manage the 
impact to business operations posed by Brexit.
• Following the appointment of a Deputy Director 
for Medical Devices, a significant piece of work was 
undertaken in leading a restructure project for the 
new medical devices department. Project managed 
by the HR and Change team, a new proposed 
structure was identified for approval by year end. 
IT Developments
• EOLAS, the HPRA’s new workflow technology 
solution, will provide the organisation with a single 
workflow and data management system to support 
its regulatory activities. It will also incorporate new 
EU standards for regulatory data management. 
During 2018, the second phase (wave 2) covering 
the implementation for human medicines and 
clinical trials was completed. This incorporated 
extensive rounds of testing, detailed end user 
training and a stabilisation period once deployed. 
Since go-live, end users have worked closely with 
the project team to identify and manage any issues 
or adjustments required.
• There were 423,473 regulatory submissions made 
through the Common Electronic Submission Portal 
(CESP), which is managed by the HPRA on behalf 
of the wider EU regulatory community. By year-end, 
there were 5,442 organisations availing of CESP 
with over 18,846 individual users. 
Quality Management
• The HPRA’s quality management team was 
responsible for overseeing the introduction of the 
General Data Protection Regulation (GDPR) which 
came into effect across Europe on 25 May 2018. 
This included the development and deployment of 
necessary policies and procedures in addition to the 
publication of a number of public and staff notices. 
There were 12 data subject requests received in 
2018. Eight of these were received prior to 25 May 
so were dealt with under the legislation in place at 
that time. The remaining four were processed under 
GDPR requirements. All requests were managed 
within the required timelines.
– New guidance documents for stakeholders, each 
of which was published on our website, included a 
guide for distributors of medical devices, a guide 
to the sale of paracetamol-containing medicines 
by non-pharmacy retailers and a guide to new 
applications and variations to wholesale distribution 
authorisations. In addition, the ICT and Business 
Services department began a project to implement 
ISO 20000-1 for service desk management.
Finance
• The HPRA is committed to the highest standards of 
corporate governance. During 2018, the financial 
statements for the previous year were prepared and 
submitted for audit to the Comptroller and Auditor 
General and subsequently published in the HPRA’s 
2017 Annual Report. All financial transactions 
during the period were reflected and reported upon 
in these statements. 
• The annual review of regulatory fees for 2019, 
incorporating a public consultation, was completed 
followed by the publication of required fee 
changes.
• Internal audit reviews took place and reports were 
issued on ICT operations and GDPR readiness. 
• New salary scales were received and systems were 
updated both in January and October.
Energy Usage
• The HPRA, as a public sector body, is required to 
report annually on its energy usage and actions 
taken to reduce consumption in accordance with 
the European Union (Energy Efficiency) Regulations 
2014 (S.I. No. 426 of 2014). As an organisation, 
we use electricity for lighting, air conditioning or 
heating as required and the provision of hot water; 
natural gas is used for central heating. In 2018, the 
HPRA consumed 773.5 MWh* of energy consisting 
of: 
– 565.3 MWh of electricity
– 208.2 MWh of fossil fuels
– 0 MWh of renewable fuels.
 Total energy reduction at year end was 33.7%, 
exceeding the goal of 33% by 2020 (as calculated 
and published by the Sustainable Energy Authority 
of Ireland (SEAI).
 * published by the SEAI 
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Authority and 
Committees
• The Authority of the HPRA met six times in 2018 
and considered a number of strategic matters 
including corporate policy, planning and financial 
matters. The latter included monthly management 
accounts, annual budgets and the financial 
statements for 2017. The Authority also reviewed 
update reports from the Statutory Advisory 
Committees and the Audit and Risk Committee. 
In addition, it reviewed the licences for all 
medicinal healthcare products as approved by the 
Management Committee.
 The number of meetings attended by each 
Authority member during 2018 was as follows:
Authority 
Member
Number of 
meetings held 
during the 
period the 
member was on 
the Authority
Number of 
meetings 
attended during 
the period the 
member was on 
the Authority
Ms. Ann Horan 
(Chairperson)
6 6
Mr. Pat Brangan 6 6
Mr. Wilf Higgins 6 6
Mr. David 
Holohan
6 6
Prof. Mary 
Horgan
4 1
Mr. Brian Jones 6 5
Prof. Elizabeth 
Keane
6 5
Prof. Caitriona 
O’Driscoll
6 6
Dr. Diarmuid 
Quinlan
6 5
– The Audit and Risk Committee, a subcommittee 
to the Authority, met four times in 2018. Further 
details are provided in the HPRA’s Financial 
Statements. 
– The Advisory Committee for Human Medicines 
met on two occasions in 2018. The Clinical 
Trials Sub-Committee is a sub-committee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year.
– The Advisory Committee for Veterinary Medicines 
met twice as did the Advisory Committee for 
Medical Devices.
– The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met twice in 2018.
• Decisions of the Authority: 
 The terms of reference of the Authority, which 
are published on the HPRA website, include 
an overview of how the Authority operates, an 
overview of all decisions taken by the Authority and 
those devolved to the Management Committee. 
 The following decisions are reserved functions of 
the Authority: 
– The Authority takes decisions relating to very 
significant and serious public and/or animal 
health matters except in circumstances where a 
meeting of the Authority cannot be convened, 
in which case the Management Committee takes 
the decision and informs the Chairperson at the 
earliest opportunity and the Authority as soon as 
is practical.  
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– The Authority refuses applications, or suspends, 
revokes or terminates authorisations as set out in 
legislation except in circumstances where: 
(a) the urgency is such that a meeting of the 
Authority cannot be convened, or 
(b) the application or authorisation is subject to a 
binding European decision, or 
(c) the application or authorisation is for a clinical 
trial or clinical investigation; in which case the 
Management Committee takes the decision 
and informs the Authority. 
– Through its Audit Committee, the Authority 
approves the internal financial controls and the 
financial audit function and satisfies itself that the 
financial controls and systems of risk management 
are robust and defensible. The Authority appoints 
the internal financial auditor. 
- The Authority approves the investment policy, 
major investments, capital projects and the terms 
of major contracts. 
- Significant acquisitions and the disposal or 
retirement of assets above a threshold set by the 
Authority are subject to Authority approval. 
- The Authority approves treasury policy and risk 
management policies. 
- The Authority approves corporate plans as 
required. 
- The Authority approves the annual budget, 
monitors expenditure and supervises the 
preparation and submission of the annual 
statutory accounts. 
- The Authority makes an annual report on the 
activities of the HPRA, including a financial 
statement, to the Minister for Health. This report 
is then published. 
- The Authority selects and appoints the Chief 
Executive, with the consent of the Minister for 
Health. The terms of office and the remuneration 
of the Chief Executive are determined by the 
Minister for Health, after consultation with the 
Authority and with the consent of the Minister for 
Finance. The Authority, through its Performance 
Review Committee, conducts a process of annual 
performance appraisal of the Chief Executive. 
Succession planning for the role of Chief 
Executive is also undertaken by the Authority. 
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Authority: Most recent  
 appointment date Expiry date
Ms. Ann Horan (Chairperson) 01/01/2016 31/12/2020
Mr. Pat Brangan 22/05/2017 31/12/2019
Mr. Wilfrid Higgins 22/05/2017 31/12/2019
Mr. David Holohan 27/01/2016 26/01/2021
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All Authority members are appointed by the Minister for Health.
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Governance Statement and 
Authority Member’s Report
Governance
The Health Products Regulatory Authority (the 
HPRA) was established under the terms of the Irish 
Medicines Board Act, 1995 (as amended), and is 
governed by an Authority which was appointed 
by the Minister for Health. The Authority of the 
HPRA (the Authority) consists of a chairperson 
and eight non-executive members. The Authority 
is accountable to the Minister for Health and is 
responsible for ensuring good governance, and 
performs this task by setting strategic objectives 
and targets and taking strategic decisions on 
all key business issues. The regular day-to-day 
management, control and direction of the HPRA 
are the responsibility of the Chief Executive and 
the Management Committee. The Chief Executive 
and the Management Committee must follow the 
broad strategic direction set by the Authority, and 
must ensure that all Authority members have a clear 
understanding of the key activities and decisions 
related to the HPRA, and of any significant risks 
likely to arise. The Chief Executive acts as a direct 
liaison between the Authority and management of 
the HPRA.
On 1 July 2014 the organisation changed its name 
from the Irish Medicines Board, as provided for 
in Section 36 of the Health (Pricing and Supply of 
Medical Goods) Act 2013 and SI (205/2014) Health 
(Pricing and Supply of Medical Goods) Act 2013 
(Commencement) order 2014.   
Authority Responsibilities
The work and responsibilities of the Authority are 
set out in the Irish Medicines Board Act, 1995 (as 
amended), as well as in the ‘Terms of Reference 
and Rules of Procedure’ of the HPRA, which also 
contains the matters specifically reserved for 
Authority decision. Standing items considered by 
the Authority include:
• declaration of interests,
• reports from committees,
• financial reports / management accounts,
• performance reports, and
• reserved matters.
The Authority is required by the Irish Medicines 
Board Act, 1995 to prepare financial statements for 
each financial year which give a true and fair view of 
the state of affairs of the HPRA and of its surplus or 
deficit for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently,
• make judgements and estimates that are 
reasonable and prudent,
• prepare the financial statements on a going 
concern basis unless it is inappropriate to presume 
that the HPRA will continue in existence, and
• state whether applicable accounting standards 
have been followed, subject to any material 
departures disclosed and explained in the financial 
statements.
 
The Authority is responsible for keeping adequate 
accounting records which disclose, with reasonable 
accuracy at any time, the financial position of 
the HPRA and which enable it to ensure that 
the financial statements comply with the Irish 
Medicines Board Act, with accounting standards 
generally accepted in Ireland and with accounting 
directions issued by the Minister for Health.  The 
maintenance and integrity of the corporate and 
financial information on the HPRA’s website is the 
responsibility of the Authority.
The Authority is responsible for approving the 
annual plan and budget. It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities.
The Authority considers that, except for the non-
compliance with the requirements of FRS102 
in relation to retirement benefits, the financial 
statements of the HPRA give a true and fair view of 
the financial performance and the financial position 
of the HPRA at 31 December 2018.
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Audit and Risk Committee
The HPRA has an audit and risk committee 
comprising three Authority members, which met 
on 4 occasions during 2018. This committee is 
responsible for reviewing internal control matters, 
together with any other issues raised by the external 
auditors, the Authority or management. The external 
auditor is invited annually to meet with the audit 
and risk committee to brief them on the outcome of 
the external audit, and the audit and risk committee 
also meets annually with the internal auditor. During 
2018 the internal auditor carried out internal audits 
on the areas of IT operations and data protection 
review, as well as a review of the system of internal 
financial controls. The audit and risk committee has 
also been involved with the review of the quality 
systems as described below.
Quality Systems
During 2018, the finance section of the HPRA 
continued the process of implementing and 
reviewing standard operating procedures (SOPs) 
under the quality management system. This process 
involved a critical review and analysis of internal 
controls and processes throughout the section 
with particular emphasis on risk management. 
This system now underpins the internal control 
environment and feeds into the internal audit 
process and ultimately into the audit and risk 
committee.
Remuneration Policy - Authority 
Members and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the Financial 
Statements. The Chairperson receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive remuneration under the 
terms of the Health (Miscellaneous Provisions) Act 
2017. All Authority members are entitled to receive 
travel expenses in accordance with circulars issued 
by the Department of Health. The Chief Executive is 
remunerated in accordance with guidelines issued 
from Government and other Executive Directors are 
paid in accordance with Department of Health pay 
scales. The remuneration of the Chief Executive and 
Executive Directors are disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of 
internal controls in use in the HPRA are described 
more fully in the Chairperson’s report on pages 58 
to 59.
Disclosures Required by Code of Practice 
for the Governance of State Bodies 
(2016)
The Authority is responsible for ensuring that the 
HPRA has complied with the requirements of the 
Code of Practice for the Governance of State 
Bodies, as published by the Department of Public 
Expenditure and Reform in August 2016. The 
following disclosures are required by the Code, 
and are contained in the notes to the financial 
statements:
• employee short term benefits breakdown,
• consultancy costs,
• legal costs and settlements,
• travel and subsistence expenditure, and
• hospitality expenditure.
Statement of Compliance
The Authority has adopted the Code of Practice for 
the Governance of State Bodies (2016) and has put 
procedures in place to ensure compliance with the 
Code. The HPRA was in full compliance with the 
Code of Practice for the Governance of State Bodies 
for 2018.
On behalf of the Authority
 
 
Date: 25 June 2019
Ms. Ann Horan 
Chairperson 
Mr. David Holohan 
Authority Member
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Statement on Internal Control
Scope of Responsibility
I, as Chairperson, acknowledge the Authority’s 
responsibility for ensuring that an effective system 
of internal control is maintained and operated. This 
responsibility takes account of the requirements of 
the Code of Practice for the Governance of State 
Bodies (2016).
Purpose of the System of Internal 
Control
The system of internal control is designed to 
manage risk to a tolerable level rather than to 
eliminate it. The system can therefore only provide 
reasonable and not absolute assurance that 
assets are safeguarded, transactions authorised 
and properly recorded and that material errors or 
irregularities are either prevented or detected in a 
timely way.
The system of internal control, which accords with 
guidance issued by the Department of Public 
Expenditure and Reform, has been in place in the 
HPRA for the year ended 31 December 2018 and up 
to the date of approval of the financial statements.
Capacity to Handle Risk
The HPRA has an audit and risk committee 
comprising three Authority members, which met on 
4 occasions during 2018.
The HPRA has outsourced the internal audit function 
to an independent professional firm, who conduct 
a programme of work as agreed with the audit and 
risk committee. During 2018 two internal audit 
reviews were conducted. Following a tendering 
process in 2018, a new firm of internal auditors were 
appointed. During 2018 the new internal auditors 
carried out a review of the system of internal 
financial controls.
The HPRA have developed a risk management 
framework, which sets out its risk appetite, the risk 
management processes in place and details the 
roles and responsibilities of staff in relation to risk. 
This framework has been made available to all 
staff, who are expected to work within the HPRA’s 
risk management policies, to alert management on 
emerging risks and control weaknesses, and assume 
responsibility for risks and controls within their own 
area of work. 
Risk and Control Framework
The HPRA has implemented a risk management 
system which identifies and reports key risks and the 
management actions being taken to address, and to 
the extent possible, to mitigate those risks.
A risk register is in place which identifies the 
key risks facing the HPRA, and these have been 
identified, evaluated and graded according to their 
significance. The register is reviewed and updated 
by management, considered by the audit and risk 
committee and presented to the Authority. The 
outcome of these assessments is used to plan and 
allocate resources to ensure risks are managed to an 
acceptable level.
The risk register details the controls and actions 
needed to mitigate risks and responsibility for 
operation of controls assigned to specific staff. I 
confirm that a control environment containing the 
following elements is in place:
• procedures for all key business processes have 
been documented,
• financial responsibilities have been assigned 
at management level with corresponding 
accountability,
• there is an appropriate budgeting system with 
an annual budget, which is kept under review by 
senior management,
• there are systems aimed at ensuring the security 
of the information and communication technology 
systems, and
• there are systems in place to safeguard the assets.
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Ongoing Monitoring and Review
Formal procedures have been established for 
monitoring control processes, and any control 
deficiencies are communicated to those responsible 
for taking corrective action, and to management and 
the Authority, where relevant, in a timely manner. 
I confirm that the following ongoing monitoring 
systems are in place:
• key risks and related controls have been identified, 
and processes have been put in place to monitor 
the operation of those key controls and report any 
identified deficiencies,
• reporting arrangements have been established 
at all levels where responsibility for financial 
management has been assigned, and
• there are regular reviews by senior management 
of periodic and annual performance and financial 
reports, which indicate performance against 
budgets.
Procurement
I confirm that the HPRA has procedures in place to 
ensure compliance with current procurement rules 
and guidelines, and that during 2018 the HPRA 
complied with those procedures.
Review of Effectiveness
I confirm that the HPRA has procedures to monitor 
the effectiveness of its risk management and control 
procedures. The HPRA’s monitoring and review of 
the effectiveness of the system of internal control is 
informed by the work of the internal and external 
auditors, the audit and risk committee which 
oversees their work, and the senior management 
within the HPRA, responsible for the development 
and maintenance of the internal control framework.
I confirm that the Authority conducted an annual 
review of the effectiveness of the internal controls 
for 2018. This review was carried out at its meeting 
on 14 March 2019.
Internal Control Issues
No weaknesses in internal control were identified 
in relation to 2018 that require disclosure in the 
financial statements.
Ms. Ann Horan 
Chairperson to the Authority 
Date: 25 June 2019
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Comptroller and Auditor General  
 
Report for presentation to the 
Houses of the Oireachtas
Qualified opinion on financial statements
I have audited the financial statements of the Health 
Products Regulatory Authority (the Authority) for the 
year ended 31 December 2018 as required under 
the provisions of section 18 of the Irish Medicines 
Board Act, 1995. The financial statements have been 
prepared in accordance with Financial Reporting 
Standard (FRS) 102 – The Financial Reporting 
Standard applicable in the UK and the Republic of 
Ireland and comprise
• The statement of income and expenditure and 
retained revenue reserves
• The statement of financial position
• The statement of cash flows and
• The related notes, including a summary of 
significant accounting policies.
In my opinion, except for the non-compliance with 
the requirements of FRS 102 in relation to retirement 
benefit entitlements referred to below, the financial 
statements give a true and fair view of the assets, 
liabilities and financial position of the Authority at  
31 December 2018 and of its income and 
expenditure for 2018 in accordance with FRS 102.
Basis for qualified opinion on financial 
statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
retirement benefit entitlements only as they become 
payable. This does not comply with FRS 102 which 
requires that the financial statements recognise the 
full cost of retirement benefit entitlements earned in 
the period and the accrued liability at the reporting 
date. The effect of the non-compliance on the 
Authority’s financial statements for 2018 has not 
been quantified.
I conducted my audit of the financial statements 
in accordance with the International Standards on 
Auditing (ISAs) as promulgated by the International 
Organisation of Supreme Audit Institutions. My 
responsibilities under those standards are described 
in the appendix to this report. I am independent 
of the Authority and have fulfilled my other ethical 
responsibilities in accordance with the standards.
I believe that the audit evidence I have obtained is 
sufficient and appropriate to provide a basis for my 
opinion.
Report on information other than the 
financial statements, and on other 
matters 
The Authority has presented certain other 
information together with the financial statements. 
This comprises the annual report, the governance 
statement and Authority members’ report and the 
statement on internal control. My responsibilities to 
report in relation to such information, and on certain 
other matters upon which I report by exception, are 
described in the appendix to this report.
I have nothing to report in that regard.
Andrew Harkness 
For and on behalf of the Comptroller  
and Auditor General 
26 June 2019 
60
FINANCIAL STATEMENTS – HPRA Annual Report 2018
Appendix to the report 
Responsibilities of Authority Members
As detailed in the governance statement and 
Authority members’ report, the Authority members 
are responsible for
• The preparation of financial statements in the form 
prescribed under section 18 of the Irish Medicines 
Board Act 1995
• Ensuring that the financial statements give a true 
and fair view in accordance with FRS 102
• Ensuring the regularity of transactions
• Assessing whether the use of the going concern 
basis of accounting is appropriate, and
• Such internal control as they determine 
is necessary to enable the preparation of 
financial statements that are free from material 
misstatement, whether due to fraud or error.
Responsibilities of the Comptroller and 
Auditor General
I am required under section 18 of the Irish Medicines 
Board Act 1995 to audit the financial statements of 
the Authority and to report thereon to the Houses of 
the Oireachtas.
My objective in carrying out the audit is to obtain 
reasonable assurance about whether the financial 
statements as a whole are free from material 
misstatement due to fraud or error. Reasonable 
assurance is a high level of assurance, but it is not 
a guarantee that an audit conducted in accordance 
with the ISAs will always detect a material 
misstatement when it exists. Misstatements can 
arise from fraud or error and are considered material 
if, individually or in the aggregate, they could 
reasonably be expected to influence the economic 
decisions of users taken on the basis of these 
financial statements.
As part of an audit in accordance with the ISAs, 
I exercise professional judgement and maintain 
professional scepticism throughout the audit. In 
doing so,
• I identify and assess the risks of material 
misstatement of the financial statements whether 
due to fraud or error; design and perform audit 
procedures responsive to those risks; and obtain 
audit evidence that is sufficient and appropriate 
to provide a basis for my opinion. The risk of not 
detecting a material misstatement resulting from 
fraud is higher than for one resulting from error, 
as fraud may involve collusion, forgery, intentional 
omissions, misrepresentations, or the override of 
internal control.
• I obtain an understanding of internal control 
relevant to the audit in order to design 
audit procedures that are appropriate in the 
circumstances, but not for the purpose of 
expressing an opinion on the effectiveness of the 
internal controls.
• I evaluate the appropriateness of accounting 
policies used and the reasonableness of 
accounting estimates and related disclosures.
• I conclude on the appropriateness of the use of 
the going concern basis of accounting and, based 
on the audit evidence obtained, on whether a 
material uncertainty exists related to events or 
conditions that may cast significant doubt on the 
Authority’s ability to continue as a going concern. 
If I conclude that a material uncertainty exists, I 
am required to draw attention in my report to the 
related disclosures in the financial statements or, 
if such disclosures are inadequate, to modify my 
opinion. My conclusions are based on the audit 
evidence obtained up to the date of my report. 
However, future events or conditions may cause 
the Authority to cease to continue as a going 
concern.
• I evaluate the overall presentation, structure and 
content of the financial statements, including the 
disclosures, and whether the financial statements 
represent the underlying transactions and events 
in a manner that achieves fair presentation.
I communicate with those charged with governance 
regarding, among other matters, the planned scope 
and timing of the audit and significant audit findings, 
including any significant deficiencies in internal 
control that I identify during my audit.
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Information other than the financial 
statements
My opinion on the financial statements does not 
cover the other information presented with those 
statements, and I do not express any form of 
assurance conclusion thereon.
In connection with my audit of the financial 
statements, I am required under the ISAs to read 
the other information presented and, in doing so, 
consider whether the other information is materially 
inconsistent with the financial statements or with 
knowledge obtained during the audit, or if it 
otherwise appears to be materially misstated. If, 
based on the work I have performed, I conclude 
that there is a material misstatement of this other 
information, I am required to report that fact.
Reporting on other matters
My audit is conducted by reference to the special 
considerations which attach to State bodies in 
relation to their management and operation. I report 
if I identify material matters relating to the manner in 
which public business has been conducted.
I seek to obtain evidence about the regularity of 
financial transactions in the course of audit. I report 
if I identify any material instance where public 
money has not been applied for the purposes 
intended or where transactions did not conform to 
the authorities governing them.
I also report by exception if, in my opinion,
• I have not received all the information and 
explanations I required for my audit, or
• The accounting records were not sufficient to 
permit the financial statements to be readily and 
properly audited, or
• The financial statements are not in agreement with 
the accounting records.
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 Note  2018  2017
  € €
Fee Income  3   23,901,603    24,033,010 
Department of Health Funding 3  4,316,000   2,941,000 
Other Income  4            888,884    655,238 
   
       29,106,487   27,629,248  
Salaries and Wages  5   21,160,214    20,284,686 
Other Operating Costs  6         5,885,565    6,650,642 
Depreciation  2         1,593,390    1,983,059 
   
       28,639,169   28,918,387 
 
Surplus/(Deficit) for the year before write
back of Superannuation contributions   467,318   (1,289,139) 
 
Staff Superannuation Contributions    696,116    924,064 
 
 
Surplus/(Deficit) for the year   1,163,434  (365,075) 
 
Balance brought forward         28,324,679    28,689,754 
 
Balance carried forward  12   29,488,113    28,324,679 
 
 
 
The Statement of Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the 
year. The Statement of Cash Flows and the notes on pages 66 to 75 form part of the financial statements.  
   
 
 
 
 
 
 
 
Statement of Income and Expenditure and Retained Revenue Reserves
For the year ended 31 December 2018
Ms. Ann Horan
Chairperson
Date: 25 June 2019
On behalf of the Authority
Mr. David Holohan
Authority Member
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 Note  2018  2017
  € €
Fixed Assets  
Property, Plant and Equipment  2      24,427,830    25,339,839 
 
Current Assets
Debtors and Prepayments 7   2,198,340   1,404,687 
Inventory of Stationery   3,498    5,133
Cash and Cash Equivalents 9    10,162,555      3,884,050 
Short Term Deposits 10   8,216,814      12,302,427   
      20,581,207    17,596,297 
Current Liabilities - Amounts falling
due within one year
Creditors and Accruals  8   10,760,912        9,058,113 
Mortgage  13           793,332    793,332 
   
      11,554,244    9,851,445
 
Net Current Assets        9,026,963          7,744,852
 
Long Term Liabilities - Amounts falling 
due after more than one year
Mortgage  13   3,966,680          4,760,012 
 
 
NET ASSETS       29,488,113      28,324,679 
 
 
Reserves
Retained Revenue Reserves  12   29,488,113      28,324,679 
  
   29,488,113       28,324,679 
 
 
 
 
Statement of Financial Position
As at 31 December 2018
Mr. David Holohan
Authority Member
Ms. Ann Horan
Chairperson
Date: 25 June 2019
The Statement of Cash Flows and the notes on pages 66 to 75 form part of the financial statements.
On behalf of the Authority
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 Note  2018  2017
  € €
Cash flows from Operating Activities
 
Surplus/(Deficit) for financial year   1,163,434  (365,075)
Depreciation of property, plant and equipment  1,593,390  1,983,059
(Profit)/Loss on Disposal of property, plant and equipment  26  0
(Increase)/Decrease in Debtors  (793,653) (275,497)
(Increase)/Decrease in Stock  1,635 (104)
Increase/(Decrease) in Creditors - amounts  
falling due within one year  1,702,799 622,819
Deposit Interest   (16,064)  (21,965)
Bank Interest  181,171 200,601
Cash from Operations  3,832,738  2,143,838
Bank Interest Paid   (181,171) (200,601)
Net Cash generated from Operating Activities  3,651,567 1,943,237
Cash flows from Investing Activities  
Deposit Interest Received  16,064 21,965
(Increase)/Decrease in Bank Deposits   4,085,613 3,289
Payments to acquire property, plant and equipment   (681,407) (1,283,637)
Receipts fom sales of property, plant and equipment  0  0
 
Net cash from Investing Activities  3,420,270 (1,258,383)
Cash flows from Financing Activities
Repayment of Borrowings  (793,332)  (793,332)
Net cash used in Financing Activities  (793,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents  6,278,505 (108,478)
Cash and Cash Equivalents at beginning of year  3,884,050  3,992,528
 
Cash and Cash Equivalents at end of year 9  10,162,555 3,884,050
 
 
Statement of Cash Flows
For the year ended 31 December 2018
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Notes to the Financial Statements
For the year ended 31 December 2018
1. Accounting Policies    
      
A. General information    
The Health Products Regulatory Authority (HPRA) 
is a public statutory body established under the 
Irish Medicines Board Act 1995 (as amended). The 
principal place of business is at Earlsfort Centre, 
Earlsfort Terrace, Dublin 2. The Health Products 
Regulatory Authority is the competent Authority for 
the regulation of medicines, medical devices and 
other health products in Ireland.    
     
B. Compliance with FRS 102    
   
The financial statements of the HPRA for the year 
ended 31 December 2018 have been prepared in 
accordance with FRS 102 (the financial reporting 
framework applicable in the UK and Ireland), as 
modified by the directions of the Minister for Health in 
relation to superannuation.
In compliance with the directions of the Minister for 
Health, HPRA accounts for the costs of superannuation 
entitlements only as they become payable (see 
K). This basis of accounting does not comply with 
FRS102, which requires such costs to be recognised in 
the year in which the entitlement is earned. 
The HPRA is availing of the reduced disclosures 
allowed by FRS 102 in relation to legal provisions, 
in instances where full disclosure might prejudice 
seriously its position in relation to disputes with other 
parties on the subject matter of the provision. 
In all other respects, the financial statements comply 
with FRS 102.      
 
C. Basis of preparation     
  
The financial statements have been prepared 
under the historical cost convention. The following 
accounting policies have been applied consistently in 
dealing with items which are considered material in 
relation to the Health Products Regulatory Authority’s 
financial statements.     
       
    
D. Critical accounting estimates and judgements
      
The preparation of the financial statements requires 
management to make judgements, estimates and 
assumptions that affect the amounts reported for 
assets and liabilities as at the reporting date and 
the amounts reported for revenues and expenses 
during the year. However, the nature of estimation 
means that actual outcomes could differ from those 
estimates. The following may involve a higher degree 
of judgement and complexity: 
  
(a) Provisions     
Provisions for legal obligations which it knows to be 
outstanding at the period-end date. These provisions 
are generally made based on historical or other 
pertinent information, adjusted for recent trends 
where relevant. However, they are estimates of the 
financial costs of events that may not occur for some 
years. As a result of this and the level of uncertainty 
attaching to the final outcomes, the actual outturn 
may differ significantly from that estimated. 
(b) Bad and Doubtful Debts   
The HPRA makes an estimate of the recoverable 
value of trade and other receivables. The HPRA 
uses estimates based on historical experience in 
determining the level of bad debts, which the 
Authority believes will not be collected. These 
estimates include such factors as the current credit 
rating, the ageing profile, historical experience of the 
particular trade receivable and objective evidence of 
impairment of the asset. Any significant reduction in 
the level of bad debt provision would have a positive 
impact on the annual surplus/deficit. The level of 
provisioning required is reviewed on an on-going 
basis and has been disclosed in the notes to the 
financial statements.
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E. Revenue recognition    
   
Revenue is measured at the fair value of the 
consideration received.    
- In the case of applications for marketing 
authorisations (new applications, variations to 
existing authorisations, or transfers) and clinical trial 
applications, income is recognised on a straight line 
basis over the specified timeline for the processing 
of the application by the Authority.    
 
- In the case of wholesale and manufacturing licences 
and maintenance of marketing authorisations, fees 
are payable annually and a full year’s income is 
accrued in each financial year.    
       
  
F. Expenditure recognition    
   
Expenditure is recognised in the financial statements 
on an accruals basis.     
       
    
G. Reporting currency and currency 
translation      
 
The financial statements are prepared in euros. 
Transactions in currencies other than euro are 
recorded at the rates ruling at the date of the 
transactions or at a contracted date. Monetary assets 
and liabilities are translated into euro at the reporting 
date or at a contracted date. Exchange differences are 
dealt with in the statement of income and expenditure 
and retained revenue reserves.    
     
       
  
H. Property, plant and equipment   
    
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated at 
cost less accumulated depreciation.   
Depreciation is calculated in order to write off the cost 
of property, plant and equipment to their estimated 
residual values over their estimated useful lives by 
equal annual instalments.   
The estimated useful lives of property, plant and 
equipment by reference to which depreciation has 
been calculated are as follows:    
    
Fixtures and Fittings:   5 years  
Computer Equipment :   3 years  
Improvements to Premises :  10 years  
       
   
Premises     
The HPRA purchased its premises at Kevin O’Malley 
House, Earlsfort Centre, Earlsfort Terrace, Dublin 2 
on 22 December 2004. The value capitalised was 
equal to the purchase price plus those costs directly 
attributable to bringing the asset into use. 
No depreciation has been calculated on the value 
of premises, as the remaining useful economic life is 
estimated to be greater than 50 years.   
     
       
I. Taxation      
 
The HPRA is exempt from liability to Corporation Tax 
under Section 227 of the Taxes Consolidation Act, 
1997.       
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J. Debtors      
 
Known bad debts are written off and specific provision 
is made for any amount the collection of which is 
considered doubtful.      
    
       
K. Superannuation     
  
The superannuation scheme operated by the 
HPRA is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 
1986. It is an unfunded statutory scheme and benefits 
are met from current income as they arise.
The scheme is a defined benefit scheme for 
employees. No provision has been made in respect of 
benefits payable. Pension payments under the scheme 
are charged to the income and expenditure account 
when paid. Contributions from employees who are 
members of the scheme are credited to the income 
and expenditure account when received. The surplus/
(deficit) for the year is shown both before and after 
superannuation deductions.
HPRA also operate the Single Public Service Pension 
Scheme. All new entrants into the public sector with 
effect from 1 January 2013 are members of this 
scheme, where all employee pension deductions are 
paid to the Department of Public Expenditure and 
Reform.
By direction of the Minister for Health, no provision 
has been made in respect of benefits payable in 
future years in relation to the Local Government 
(Superannuation Revision) (Consolidation) Scheme 
1986 or the Single Public Service Pension Scheme.
In order to help meet the cost of benefits payable 
in future years, reserves have been split between 
retained reserves and superannuation reserves, which 
consist of employee superannuation contributions.
This split is shown in note 12 - Movement on Income 
and Expenditure Reserves.    
       
     
       
  
L. Provisions      
 
A provision is recognised when the HPRA has a 
present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the HPRA 
and a reliable estimate can be made of the amount of 
the obligation. 
M. Library      
 
No value has been placed on the books, audio-visual 
resources and electronic databases in the library. 
Expenditure on these items is written off in the year in 
which it is incurred.     
   
       
N. Leases      
 
All leases are treated as operating leases and the 
rentals thereunder are charged to the Statement of 
Income and Expenditure and Retained Revenue 
Reserves on a straight line basis over the lease period.  
       
      
O. Loans      
 
Loans are recognised initially at the transaction price 
(present value of cash payable, including transaction 
costs). Loans are subsequently stated at amortised 
costs. Interest expense is recognised on the basis 
of the effective interest method and is included in 
finance costs.
Loans are classified as current liabilities unless there is 
a right to defer settlement of the loan for at least 12 
months from the reporting date.    
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2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total 
 and equipment Fittings Equipment Improvements To Premises   
  € € € € € €
  Cost
  Balance as at   1,227,396        15,783,805            502,445          4,374,608    23,156,037   45,044,291
  1 January 2018  
  Additions for the year            12,145    669,262  -   -   -  681,407
  Disposals for the year (960) (11,451) -  -  -  (12,411)
  As at 31 December 2018      1,238,581       16,441,616            502,445          4,374,608    23,156,037   45,713,287
  Depreciation
  Balance as at   1,171,859       14,132,920             502,445         3,897,228   -   19,704,452
  1 January 2018
  Charge for the year            25,358          1,457,728  -   110,304   -  1,593,390
  Disposals for the year  (934) (11,451) -  -  -  (12,385)
  As at 31 December 2018   1,196,283       15,579,197             502,445          4,007,532   -  21,285,457
  Net Book value at  
 31 December 2018            42,298    862,419   -   367,076   23,156,037   24,427,830
  Net Book value at 
  1 January 2018   55,537   1,650,885  -  477,380    23,156,037   25,339,839
3.  Income  2018  2017
  €  €
 Fee Income
 Clinical Trials   210,844    192,843 
 Human Medicine - National Fees   6,927,684         6,196,699 
 Human Medicine - European Fees   7,311,717         7,050,808 
 Veterinary Medicine - National Fees   1,856,343         1,553,918 
 Veterinary Medicine - European Fees   1,662,060         1,499,930 
 Compliance Department   4,925,873   4,765,340 
 Medical Devices   1,565,944         2,920,161  
  
   24,460,465       24,179,699 
 Movement in deferred revenue (558,862)   (146,689) 
   23,901,603       24,033,010 
 Dept Of Health Funding (Vote 38 Subhead E1)   4,316,000        2,941,000  
 Other Income (Note 4)   888,884           655,238 
  
 Total Income   29,106,487      27,629,248 
 
Certain fees received by the Authority under the Irish Medicines Board Act 1995 (as amended), totalling €19,258,941 
in 2018, shall be paid into or disposed of for the benefit of the Exchequer in such manner as the Minister for Public 
Expenditure and Reform directs.
The HPRA is in discussions with its parent department, as it is some years since the Minister has issued a directive in 
relation to the fees under Section 13 of the IMB Act.
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4.  Other Income
  2018  2017
  €  €
  
 Conference Fee Income   181,842    58,900 
 Deposit Interest   16,064               21,965 
 (Loss)/Gain on Disposal of Fixed Assets  (26)     - 
 IT Income   614,250    519,250 
 Zambia Project Income  76,754   55,123
   
  888,884  655,238
5.  Salaries and Wages    
 
 Basic Pay     18,265,668      17,333,455  
 Overtime     12,465           6,250 
 Allowances    169,636      167,802  
 Staff Short Term Benefits    18,447,769      17,507,507  
 Retirement Benefit Costs    885,825      1,061,363  
 Employer’s Contribution to Social Welfare    1,826,620      1,715,816  
   
      21,160,214       20,284,686
 
  
The average number of staff employed during the year was 332 (2017 - 327).  
Payroll numbers at 31 December 2018 can be analysed across the following departments:    
    
  
 
 Chief Executive  3  3
 Compliance  63  69
 Finance, Corporate & International  24  23
 Human Products Authorisation & Registration  101  110
 Human Products Monitoring  33  49
 Human Resources & Change  9  9
 IT & Business Services  21 19
 Medical Devices 36  -
 Quality, Scientific Affairs & Communications 13  12
 Veterinary Sciences  32  28
 Staff  335  322
 Authority Members 7  7
 Pensioners  39  38
  381  367
 
 
One termination or severance payment was made during the year.  
Pension related deductions for Public Servants of €874,626 were deducted from staff during the year and paid over to the 
Department of Health.
Pension deductions for Public Servants who are members of the Single Public Service Pension Scheme of €254,928 were 
deducted from staff during the year and paid over to the Department of Public Expenditure and Reform.
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 Salary Band 2018  2017
  
 €0 to €60,000    213  202
 €60,001 to €70,000    47  63 
 €70,001 to €80,000    27  13 
 €80,001 to €90,000    11  15 
 €90,001 to €100,000    20  22 
 €100,001 to €110,000    10  3 
 €110,001 to €120,000    4  1 
 €120,001 to €130,000    1  2 
 €130,001 to €140,000    1  - 
 €140,001 to €150,000    -  1
 €150,001 to €160,000    1 - 
     
    335  322  
 
 Average Salary    €54.6K  €52.4K 
 
Higher salaries relate primarily to scientific and other professional staff e.g. clinicians, pharmacists, veterinarians, lawyers 
etc and are in accordance with Department of Health salary scales.
For the purposes of this disclosure, short-term employee benefits in relation to services rendered during the reporting period 
include salary, overtime, allowances and other payments made on behalf of the employee, but exclude employer’s PRSI.  
   
6.  Operating Costs
  2018  2017
  €  €
  
 Accommodation Costs    1,210,891     1,177,395 
 Travel, Representation and Training   1,304,837     909,186
 Bank Charges and Interest   187,696      207,643 
 Legal Fees   657,437      614,829 
 Audit Fees   32,791      28,578 
 Stationery, Publications, Postage and Communications    578,144      637,177  
 Consultancy    331,390      325,354  
 Sampling and Analysis   252,748                   244,789  
 Other Operating Costs    1,329,631                2,505,691  
   
   5,885,565             6,650,642 
  
  
Travel costs include an amount of €14,973 related to staff hospitality, and an amount of €537,121 related to travel and 
subsistence, of which €213,826 is national and €323,295 is foreign.
No costs were incurred in relation to client hospitality. Legal fees are in relation to ongoing legal proceedings, and do 
not include any amounts in relation to conciliation, arbitration or settlement payments.
Consultancy costs comprise €151,086 related to public relations/marketing, €163,343 related to human resources/
pensions and €16,961 related to other.   
  
 
71
FINANCIAL STATEMENTS – HPRA Annual Report 2018
Employee’s short term benefits are categorised into the following bands:
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7.  Debtors (all due within one year) 2018  2017
  €  €
 
 Trade Debtors   1,852,256    991,758 
 Prepayments  211,940                 256,440 
 Other Debtors   134,144    156,489 
   
   2,198,340    1,404,687
Trade debtors are shown net of the bad debt provision.
8. Creditors (amounts falling due within one year)   
 
 
 Trade Creditors   189,511                226,101
 Accruals   8,129,067    7,018,843 
 Deferred Revenue   1,808,497              1,249,634 
 Revenue Commissioners              633,837                563,535  
  
         10,760,912              9,058,113 
9. Cash and Cash Equivalents    
  
  
 Cash at Bank and in Hand      4,027,728   730,979 
 Demand Deposits (Convertible to Cash on Demand)      6,134,827        3,153,071 
 
            10,162,555      3,884,050 
 
10. Short Term Deposits     
 
 
 Short Term Deposits (not immediately convertible to cash)   8,216,814         12,302,427 
  
          8,216,814           12,302,427 
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged:    
 Auditor’s Remuneration   18,000  18,000
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12.   Movement on Income and  
    Expenditure Reserves 
    As At  Income &  Transfer To As At 
   01/01/2018  Expenditure   Pension Reserve  31/12/2018 
    € €  € € 
  
  Retained Reserves   18,544,652  467,318    (400,000)  18,611,970 
Staff Superannuation Contributions           9,780,027    696,116    400,000 10,876,143  
 
       28,324,679  1,163,434   0 29,488,113  
Our Audit and Risk Committee recommended the transfer of a further €400,000 in 2018 from retained reserves to 
the superannuation reserve as a result of a number of recent and upcoming retirements, where the costs are quite 
significant.     
   
 
13. Long Term Liabilities   
    
  Mortgage
 On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises of €20,400,000 over 20 years from 
Bank of Ireland Corporate Lending.     
 
The HPRA is committed to making the following capital repayments on its mortgage :   
    
    
 
  2018  2017
      €  € 
 
  - within one year             793,332               793,332 
  - between one and five years          3,173,328            3,173,328 
  - after five years     793,352           1,586,684 
   
       4,760,012    5,553,344 
14. Interest Rate Exposure   
 
 The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings for the 
mortgage duration. The balance of the borrowings are fully offset by cash reserves. As the mortgage is at a fixed rate, 
the Authority has no interest rate exposure.     
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15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €285,984 in relation to operating leases. 
 
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, Alexandra House, Earlsfort Centre,  
 Dublin 2. At 31 December 2018 this lease had 3 years and four months remaining.   
    
    
  2018  2017
   €  €
 The amounts due under this lease are as follows:
 - within one year  285,984   285,984
 - between one and five years   667,296    953,280 
 - after five years  -   -
   
   953,280     1,239,264 
16. Capital Commitments   
     
 Contracted For (Contract Signed)     1,404,356   1,775,842 
   
     1,404,356    1,775,842 
 
17. Authority Remuneration Fees  Expenses
   €  €
  
 Ms. Ann Horan (Chairperson)           11,970               659 
 Mr. Pat Brangan             7,695                 1,159 
 Mr. Wilfrid Higgins            7,695                 379 
 Mr. David Holohan           7,695               762 
 Prof. Mary Horgan            0                 711 
 Mr. Brian Jones             7,695                 3,041
 Dr. Elizabeth Keane           7,695               572 
 Prof. Caitriona O’Driscoll             0                 924 
 Dr. Diarmuid Quinlan            7,695                 179
   
     58,140       8,386  
Up to the 15 February 2017, other than the Chairperson, no other Authority Member received a salary. On 16 February 
2017, the Health (Miscellaneous Provisions) Act was enacted, which made provision for payment of fees to other 
Authority members, provided that they were in compliance with the ‘one person one salary’ principle. Two Authority 
members do not receive a fee under this principle. 
Authority expenses comprise €6,410 domestic and €1,976 foreign.   
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18. Key Management Personnel Remuneration 2018  2017
   €  €
    
 Chief Executive   151,500   146,123
 Senior Management   832,051     862,273 
   
    983,551     1,008,396 
  
  
All payments to key management personnel were in respect of salaries and short term employee benefits. No post-
employment benefits or termination benefits were paid. 
The Chief Executive’s and senior management’s pension entitlements do not extend beyond the standard entitlements 
in the model public sector defined benefit superannuation scheme.   
   
  
19. Related Party Transactions
  
 There have been no transactions with related parties which require disclosure under Financial Reporting Standard 102.
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in relation to prompt 
payment of accounts.
21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows: 
  
 2018      €1 = STG £0.85680
 2017       €1 = STG £0.86470
22. Provisions
 
The HPRA has been notified of a number of legal proceedings or potential proceedings. The Authority has provided 
in full for its ‘best estimate’ of the expenditure it is likely to incur in relation to those cases. The Authority is availing of 
the reduced disclosures allowed by FRS 102 in instances where full disclosure might prejudice seriously its position in a 
dispute with other parties on the subject matter of the provision.   
 
23. Going Concern
 
 The HPRA has a reasonable expectation, at the time of approving the financial statements, that the HPRA has adequate 
resources to continue its operations. For this reason, the HPRA continues to adopt the going concern basis in preparing 
the financial statements.    
 
 
24. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 02 May 2019.
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2018 Committee Members
Management Committee
Dr. Lorraine Nolan  
Chief Executive 
Ms. Rita Purcell   
Deputy Chief Executive
Dr. Gabriel Beechinor  
Director of Veterinary Sciences
Dr. Caitríona Fisher   
Director of Quality, Scientific Affairs 
and Communications
Dr. Joan Gilvarry   
Director of Human Products 
Monitoring
Mr. Kevin Horan
Director of Information Technology 
and Business Services 
Mr. John Lynch   
Director of Compliance
Dr. Niall MacAleenan  
(Appointed February 2018) 
Deputy Director of Medical Devices
M. Lynsey Perdisatt 
Director Human Resources and 
Change
Ms. Grainne Power  
(Appointed July 2018) 
Director of Human Products 
Authorisation and Registration
Authority (Board)
Ms. Ann Horan – Chairperson
Dr. Patrick Brangan
Mr. Wilfrid Higgins
Prof. Mary Horgan  
(Resigned July 2018)
Mr. David Holohan
Mr. Brian Jones
Prof. Elizabeth Keane
Prof. Caitriona O’Driscoll
Dr. Diarmuid Quinlan
Audit Committee
Dr. Patrick Brangan – Chair
Mr. David Holohan
Prof. Elizabeth Keane
Advisory Committee for 
Human Medicines
Prof. Mary Horgan – Chair 
(Resigned July 2018)
Dr. Kevin Connolly
Prof. Desmond Corrigan
Ms. Maria Egan
Prof. Tom Fahey
Prof. David Kerins
Ms. Fionnuala King
Prof. Patrick Murray
Dr. Fionnuala Ní Ainle
Dr. Brian O’Connell
Mr. Ronan Quirke
Dr. Patrick Sullivan
Advisory Committee for 
Veterinary Medicines
Mr. Patrick Brangan – Chair
Dr. Ruadhrí Breathnach 
Ms. Eugenie Canavan
Dr. Martin Danaher  
(Resigned September 2018)
Dr. Helena Kelly
Dr. Nola Leonard
Dr. Bryan Markey
Dr. Ciaran Mellett
Dr. Warren Schofield
Dr. Robert Shiel
Dr. Christina Tlustos 
Advisory Committee for 
Medical Devices
Mr Wilfrid Higgins – Chair
Prof. David Barton  
(Resigned December 2018)
Dr. Vivion Crowley
Mr. Ger Flynn
Dr. Fergal McCaffrey
Ms. Margaret O’Donnell
Prof. Martin O’Donnell
Prof. Richard Reilly
Prof. Mary Sharp
Mr. Sean-Paul Teeling
Prof. Sean Tierney
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Clinical Trial  
Sub-Committee of 
Advisory Committee for 
Human Medicines
Dr. Patrick Sullivan – Chair
Dr. Liam Bannan
Dr. Geraldine Boylan
Dr. Paul Browne
Dr. Peter Crean
Prof. Lee Helman (CT Expert)
Dr. Filip Janku (CT Expert)
Dr. Catherine Kelly
Dr. Patrick Morris
Dr. Thomas Peirce 
Dr. Bryan Whelan
Dr. Jennifer Westrup
Experts Sub-Committee of 
the Advisory Committee 
for Human Medicines
Prof. Mary Horgan – Chair 
(resigned July 2018)
Dr. Linda Coate
Dr. Kevin Connolly
Mr. James Colville
Dr. Noreen Dowd
Dr. Stephen Eustace
Prof. Stephen Flint
Dr. Tim Fulcher
Dr. Joseph Galvin
Dr. Patrick Gavin
Dr. Paul Gallagher
Dr. Kevin Kelleher
Dr. Catherine Kelly
Dr. Mary Keogan
Prof. David Kerins
Dr. Mark Ledwidge
Dr. Frank Murray
Dr. Yvonne O’Meara
Dr. Cormac Owens
Dr. Jogin Thakore
Dr. Gerry Wilson
Advisory Sub-Committee 
for Herbal Medicines
Prof. Des Corrigan – Chair
Dr. James Barlow
Dr. Kevin Connolly
Mrs. Ingrid Hook
Ms. Claudine Hughes
Ms. Anna-Maria Keaveney
Dr. Celine Leonard
Dr. Donal O’Mathuna
Dr. Camillus Power
Dr. Helen Sheridan
Dr. Emma Wallace
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Presentations 2018
Third Level / Professional Development Presentations and Training 
Institution Course Presentation Title
An Garda Síochána Garda Seminar Approaches to Combating the 
Unauthorised Sale of Medicines
DG SANTE Better Training for Safer Food (BTSF) Approaches to Combating the Online 
Sale of Prescription Medicines
DIT Clinical Laboratory Science Medical Devices and HPRA
DIT Clinical Laboratory Science Near Patient Testing And Vigilance
GMIT / IT Sligo Medical Technology Regulatory 
Affairs and Quality
New European Regulations on 
Medical Devices
INFARMED Joint Action on Market Surveillance 
(JAMS)
JAMS Work Package 5 Status Update
IT Sligo Medical Biotechnology and 
Pharmaceutical Science
GMP, Quality Defects, Biological 
Medicines and Pharmacovigilance 
(Case Study based Workshop)
Letterkenny IT Veterinary Nursing Regulation of Veterinary Medicinal 
Products
NIBRT/AbbVie Bioprocessing and Biologic 
Medicines
Regulation of Biological and 
Biosimilars
RCSI Careers Seminar Career Overview including 
Information on Pharmacovigilance
RCSI Nurse / Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
RCSI Pharmacy Quality Defect Investigations and 
Product Recalls
RCSI Pharmacy Regulation Biotech Therapeutics
RCSI Pharmacy Regulation of Biosimilars
RCSI Pharmacy Regulation of Biotechnological 
Therapeutics
RCSI Pharmacy Regulation of Generic Medicines
RCSI Pharmacy Regulation of Generic Medicines and 
Interchangeable Medicines
RCSI Pharmacy Regulation of Medicines
St Johns, Cork Veterinary Nursing Regulation of Veterinary Medicinal 
Products
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St Patrick's University Hospital Staff Seminar Approaches to Combating the 
Unauthorised Sale of Medicines
TCD Immunology Regulation of Biological Medicinal 
Products
TCD Immunology Regulation of Medicines
TCD Pharmaceutical Medicine Biological Medicinal Products:  
A Regulatory Perspective
TCD Pharmaceutical Medicine Biological Medicine Products:  
A Regulatory Perspective
TCD Pharmaceutical Medicine Communication of Safety Data and 
Overview of WHO Programme for 
International Drug Monitoring
TCD Pharmaceutical Medicine Legal Provisions Governing Product 
Information
TCD Pharmaceutical Medicine Supporting Innovation through 
Regulation and Science
TCD Pharmaceutical Medicine The Role of the CMDh
TCD Pharmacy Authorisation of Medicines
TOPRA Writing Effective Product Information The SmPC: Regulators Perspective
UCC Pharmacy Quality Defect Investigations and 
Product Recalls
UCC Safe Prescribing Workshop Notification of adverse reactions
UCD Nurse / Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
UCD Regulatory Affairs Regulation of Biological Medicinal 
Products
UCD Regulatory Affairs Regulation of Biological Medicinal 
Products
University of Limerick Regulatory Affairs Compiling a Successful Clinical Trial 
Application 
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Event / Organiser Presentation Title
AdvaMed MDR/IVDR Implementation 
AESGP Impact of the new European Medical Devices 
Regulation
Animal Health Awards HPRA Introduction
BEAI Information Session Introduction to UDI in the MDR / IVDR
BEAI Information Session New EU Medical Devices Regulations
Biopharma Ambition Conference European Regulation for the 21st Century - The Path 
Forward
British Pharmacology Society Comparability of Biomedicines: Acceptable 
Differences in Quality Attributes
CAMD Brexit - HPRA Perspective on Medical Devices
CAMD Joint Action on Market Surveillance of Medical 
Devices
CAMD Medical Device Fees in Ireland
CAMD Outcome of Questionnaire on Fees for Medical 
Devices
CAMD Outputs of the UDI Taskforce
Clinical Research Development Ireland (CRDI) Regulation of Clinical Research of Medical Devices
CRDI The Perspective of the Regulator
Danish Medicines Agency The EU Regulatory Framework for the Application of 
3Rs in Developing and Testing Veterinary Medicines
DCU Brexit Institute Brexit – Medicine and Public Health
Department of Health, Department of Agriculture, 
Food and the Marine, HSE
European Antibiotics Awareness Day (HPRA 
information stand)
DIA CMC Workshop Drug-Device Combinations: Some Regulatory 
Considerations
DIA CMC Workshop How to Maximise the Effectiveness of Prior 
Knowledge in CMC Submissions
DIA EuroMeeting A Regulatory Authority Perspective on the New EU 
Devices Regulations
DIA Europe ICMRA Plenary Governance Project Update
DIA Japan Recent Trends in Pharmaceuticals Regulations 
Globally
DIA Japan ICMRA Plenary Introduction to ICMRA and the Innovation Project
EMA Stakeholder Workshop Process Validation and Accelerated Access – 
Challenges and Solutions
ENVI Committees (European Parliament) Implementation of the Medical Devices Regulations
European Compliance Academy (ECA) Continuous Manufacturing
GIRP Safety Features – Implications for Wholesalers
GIRP Annual Conference Smart Regulation for Healthcare Innovation in Europe
Regulatory Presentations
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HMA Working Group of Enforcement Officers The Road Ahead: WGEO and the HMA Strategy
ICDA Irish Cosmetic Regulatory Landscape
IDA (India) Research, Collaboration, Funding and Regulatory 
Landscape for Global Biopharma Companies in 
Ireland
IDA Ireland Medical Devices Regulation in Ireland
IMSTA Information Session HPRA Brexit Preparedness for Medical Devices
IMSTA Information Session Regulation (EU) 2017/746 on IVDs
IPU Seminar Brexit and the Supply of Medicines
Ireland Active Conference Zero Gains Campaign - The Dangers of Using 
Anabolic Steroids
Irish Medical Organisation Responding to Brexit Challenges and Opportunities
Irish Medtech Association Changing Medical Devices Regulation
ISPE ATMP Seminar ATMPs - A Regulatory Perspective
Medicines for Europe Conference Responding to Brexit Challenges and Opportunities
MHRA / JAMS Status Update on JAMS Work Package 5
Nordic Regulatory Affairs Meeting HPRA's Initiative to Maintain Medicine Supplies Post 
Brexit
PDA/FDA Regulatory Conference The Evolving Regulatory Landscape: An EU and 
PIC/S Perspective
PFIPC (Enforcement Forum) Approaches to Combating the Unauthorised Sale of 
Medicines
Pharma Technical Seminar (EU Commission) HPRA Brexit Preparedness
PHECC Inspection of Controlled Drug Sites with Advanced 
Paramedic and Paramedic Access
Pompidou Group (Council of Europe) Investigating of the Online Supply of Medical 
Products
RAPS CAMD and Roadmap Update
Reducing Medication Errors in Healthcare Services 
Conference 
Medication Errors – The Role of the Regulator
TOPRA Annual Symposium Cooperation on Combinations and Borderlines
TOPRA Annual Symposium Outcomes of ICDRA Dublin 2018
TOPRA Annual Symposium Progress on MDR / IVDR
Appendix 3
Publications and Articles 2018
Drug Safety Newsletters
Edition Topics
March 
86th Edition
– Esmya (ulipristal acetate) – Important new warnings of serious liver injury and 
recommendations for liver monitoring
– Xofigo (radium-223 dichloride) – Contraindication in combination with Zytiga (abiraterone 
acetate) and prednisolone/prednisone
– Mycophenolate – Updated contraceptive advice for male patients
– Oral retinoids – Outcome of EU review and updated warnings
– Zinbryta (daclizumab beta) – EMA recommendation for immediate suspension and recall
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
April 
87th Edition
– Epilim (valproate) – New contraindications, strengthened warnings and measures to 
prevent exposure during pregnancy
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
June 
88th Edition
– Granulocyte Colony Stimulating Factors (G-CSFs) – Risk of aortitis
– Ocaliva (obeticholic acid) – Risk of serious liver injury in patients with pre-existing  
moderate or severe hepatic impairment – Reminder of differential dosing 
recommendations
– Clarithromycin – Reminder regarding cardiovascular safety and risk minimisation advice
– Adverse Reaction Reporting – Reminder
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
August 
89th Edition
– Xofigo (radium-223 dichloride) – New restrictions for use
– Champix (varenicline) – Product information Update – Reports of Transient Loss of 
Consciousness
– Oral Methotrexate – Updates to product Information
– Adverse Reaction Reporting – Update
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
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November 
90th Edition
– Xarelto (rivaroxaban) – Increase in all-cause mortality, thromboembolic and bleeding 
events in patients after transcatheter aortic valve replacement in a prematurely stopped 
clinical trial.
– Insulin-containing products – Risk of medication errors associated with extraction of 
insulin from pre-filled pens and cartridges for reusable pens.
– Hydrochlorothiazide (HCTZ) – Risk of non-melanoma skin cancer (NMSC)
– Dolutegravir – Neural tube defects reported in infants 
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
December 
91st Edition
– Fluoroquinolone antibiotics – EU review advises restrictions for certain infections and 
warns of rare but serious long lasting adverse reactions
– Adverse Reaction Reporting – Reminder
Human Medicines Articles – External Publications
Month Publication Topics
January MIMS – Quinine – Reminder of safety profile and potential for  
Drug-Drug interactions particularly where used for nocturnal 
leg cramps
February IMF – New CPD e-learning module on reporting suspected 
adverse reactions
MIMS – Educational materials and tools for medicines published on 
HPRA website
MIMS Respiratory 
Supplement
– Amoxicillin-very rare reports of DRESS
March MIMS – New contraindication for injectable methylprednisolone 
products containing lactose in patients with cows milk allergy
MIMS Cardiovascular 
Supplement
– Domperidone containing medicines - reminder of the 
risk of cardiac adverse reactions, restricted indication, 
contraindications, reduced dose and duration of use
April MIMS – Gabapentin – Respiratory depression without concomitant 
opioid use
MIMS Oncology 
Supplement
– Xofigo (radium-223 dichloride) – Contraindication in 
combination with Zytiga (abiraterone acetate) and 
prednisone/prednisolone
May MIMS – Epilim (valproate) – New contraindications, strengthened 
warnings and measures to prevent exposure during 
pregnancy
June MIMS – Mycophenolate – Updated contraceptive advice for male 
patients
MIMS Diabetes 
Supplement
– Educational materials and tools for medicines published on 
HPRA website
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July MIMS (July/August 
issue)
– Clarithromycin – Reminder of cardiovascular safety and risk 
minimisation advice
MIMS Respiratory 
Supplement (July/
August issue)
– Adverse Reaction Reporting - Reminder
August IMF – Epilim (valproate) – New contraindications, strengthened 
warnings and measures to prevent exposure during 
pregnancy
September MIMS – Xofigo (radium-223 dichloride) – New restrictions for use
MIMS Rheumatology 
Supplement
– Oral Methotrexate – Updates to Product Information
October MIMS – Ocaliva (obeticholic acid) – Risk of serious liver injury with 
pre-existing moderate or severe hepatic impairment
MIMS Women’s Health 
Supplement
– Epilim (valproate) – New contraindications, strengthened 
warnings and measures to prevent exposure during 
pregnancy
November MIMS – Champix (varenicline) – Product Information update – 
Reports of Transient loss  of consciousness
MIMS Diabetes 
Supplement
– Insulin-containing products – Risk of medication errors 
associated with extraction of insulin from pre-filled pens and 
cartridges for reusable pens
December MIMS – Hydrochlorothiazide (HCTZ) – Risk of non-melanoma skin 
cancer (NMSC)
MIMS Compendium – Epilim (valproate) – New contraindications, strengthened 
warnings and measures to prevent exposure during 
pregnancy
Veterinary Medicines Articles – External Publications 
Publication Topic
Veterinary Ireland Journal Brexit impact on availability
It’s Your Field Availability of veterinary medicines in Ireland
It’s Your Field The future availability of veterinary medicines: Latest developments
It’s Your Field Factors affecting the availability of veterinary medicines in Ireland
It’s Your Field Use of antibiotics in dairy cows
New Industry Guidance Documents  
Document Title Month
Guide for distributors of medical devices February
Guide to new applications and variations to wholesale distribution authorisations December
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Appendix 4
European and National Committee / 
Working Group Participation
Committee/Working Group Organisation Meetings 
in 2018
Counterfeiting of Medical Products (CMED) Council of Europe 1
Market Surveillance Forum Department of 
Business, Enterprise 
and Innovation
3
Working Group on Cybercrime Council of Europe 1
Good Distribution Practice for Veterinary Medicines Department of 
Agriculture, Food and 
the Marine
1 
Medicinal Cannabis Expert Reference Group Department of Health 8
National Clinical Effectiveness Committee (NCEC) Department of Health 4
Safety features – National coordination group Department of Health 8
National Interdepartmental AMR Consultative Committee Departments of Health 
/ Agriculture, Food 
and the Marine
1
EDQM Committee Meetings EDQM 1
European Network of Official Cosmetics Control Laboratories 
(OCCL)  
EDQM 1
National Pharmacopoeia Authorities – Annual Meeting EDQM 1
OMCL (Official Medicines Control Laboratories) Network EDQM 2
OMCL Network Active Pharmaceutical Ingredient (API) Working 
Group
EDQM 2
OMCL Network Centrally Authorised Products (CAP) Working 
Group
EDQM 1
OMCL Network Communications Working Group EDQM 2
OMCL Network Counterfeit Products Working Group EDQM 1
OMCL Network Mutual Recognition and Decentralised procedures 
(MRP/DCP) Working Group
EDQM 1
OMCL Network Uncertainty of Measurement Working Group EDQM 2
Tissues & Cells Good Practice Guidelines – drafting group EDQM 2
Biological Working Party EMA 11
Biosimilar Medicines Working Party (BMWP) – including telecons EMA 7
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Committee for Advanced Therapies (CAT) EMA 11
Committee for Herbal Medicinal Products (HMPC) EMA 6
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
Efficacy Working Party – Veterinary EMA 4
Good Clinical Practice (GCP) Inspectors’ Working Group (including 
training seminar)
EMA 3
Good Manufacturing and Distribution Practice (GMDP) Inspectors’ 
Working Group (including meeting of Brexit sub-group)
EMA 3
Heparin Working Group EMA 1
Immunological Working Party - Veterinary EMA 3
MAH Good Manufacturing Practice (GMP) responsibilities Working 
Group
EMA 4
Paediatric Committee (PDCO) EMA 12
Pharmacovigilance (PV) Inspectors’ Working Group (human) EMA 4
Pharmacovigilance (PV) Inspectors’ Working Group (veterinary) EMA 4
Pharmacovigilance Business Team EMA 8
Pharmacovigilance Risk Assessment Committee (PRAC) EMA 11
Pharmacovigilance Working Party - Veterinary EMA 6
Plasma Master File Meetings - telecon EMA 5
Process Analytical Technology – including telecon EMA 4
Quality Defects - Best Practices Working Group EMA 1
Quality Defects - Risk Working Group EMA 2
Quality Defects and Rapid Alert Working Group EMA 2
Quality Review of Documents Working Groups EMA 3
Quality Working Party EMA 4
Safety Working Party – Human EMA 12
Safety Working Party – Veterinary EMA 4
Scientific Advice Working Party – Human EMA 11
Scientific Advice Working Party – Veterinary EMA 11
Signal Management Review Technical Working Group (Methods) – 
PRAC 
EMA 2
Signal Management Review Technical Working Group (SMART) 
Processes – PRAC 
EMA 8
Competent Authorities on Blood and Blood Components European Commission 2
Competent Authorities on Organ Donation and Transplantation European Commission 1
Competent Authorities on Tissues and Cells European Commission 1
Expert Group on Clinical Trials European Commission 3
Expert Group on Precursor Chemicals European Commission 1
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Expert Sub-Group on Vigilance for Blood, Tissues and Cells,  
and Organs (VES)
European Commission 2
Expert Working Group on Safety Features (including meetings, 
telecons & workshop with EMVO)
European Commission 10
IVD Classification working group European Commission 5
IVD Technical Group European Commission 3
IVD-CIE Working group European Commission 3
Joint Action Market Surveillance of Medical Devices (MDs) 
(including telecon)
European Commission 7
Medical Device – Vigilance MIR Form Development European Commission 2
Medical Device Compliance and Enforcement working group 
(COEN) 
European Commission 2
Medical Device Coordination Group European Commission 4
Medical Device Expert Group Vigilance Working group European Commission 2
Medical Device Periodic Safety Update Reports Working Group European Commission 3
Medical Device Periodic Summary Report Working Group European Commission 14
Medical Device Regulatory Committee European Commission 1
Medical Device Vigilance Eudamed Working Group European Commission 4
Medical Device Vigilance Guideline Revision 9  European Commission 4
Notified Body Operations Group European Commission 2
Platform of European Market Surveillance Activities in Cosmetics 
(PEMSAC) – Market Surveillance
European Commission 2
Rapex System European Commission 1 
Standing Committee on Cosmetic Products European Commission 3
Working Group on Cosmetic Products European Commission 3
Vigilance and Inspection for the Safety of Transfusion,  
Assisted Reproduction and Transplantation (VISTART)  
European Commission 
/ Health and Food 
Executive Agency
1 
Vigilance and Inspection for the Safety of Transfusion,  
Assisted Reproduction and Transplantation (VISTART)
European Commission 
/ National Competent 
Authorities
2 
Operation MisMed Europol 1
Operation Viribus Europol 1
Food Fraud Task Force Food Safety Authority 
of Ireland (FSAI)
2
Clinical Trials Facilitation Group (CTFG) HMA 6
CMDh / GCP Inspectors Sub-Group HMA 1 
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Human (CMDh)
HMA 11
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Veterinary (CMDv)
HMA 11
Homeopathic Medicinal Products Working Group HMA 3
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Pharmacovigilance Worksharing Procedures Working Party HMA 11
Risk-based Surveillance Testing – Drafting Group (including 
telecons)
HMA 6
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers (WGEO) (including 
management committee)
HMA 4
Working Group of Quality Managers HMA 2
Device Specific Vigilance Guidance for Insulin Pumps and 
integrated pump and meter systems
HPRA 2
National Cosmetics Surveillance Forum HPRA / HSE 4
International Medical Device Regulators Forum (IMDRF) 
Management Committee
IMDRF 1
Operation Pangea (including liaison meetings) Interpol 6
Safety features – Irish Medicines Verification Organisation (IMVO) IMVO 3
Competent Authorities for Medical Devices (CAMD) National Competent 
Authorities
2
Quarterly Haemovigilance Meetings NHO / HPRA 4
National Standards Authority of Ireland (NSAI) – Cosmetic 
Standards 
NSAI 2
Organ Vigilance Working Group ODTI / HPRA 2
Permanent forum on International Pharmaceutical Crime (PFIPC) 
annual meeting
PFIPC 2
Pharmaceutical Inspection Co-Operation Scheme (PIC/S) 
Committee of Officials
PIC/S 1
PIC/S Executive Bureau PIC/S 2
PIC/S Expert Circle on Quality Risk Management (QRM) (including 
telecon)
PIC/S 9
PIC/S Sub-Committee on Compliance (including telecon) PIC/S 2
PIC/S Sub-Committee on Harmonisation PIC/S 2 
UN office of Drugs and Crime (UNODC) – Expert Groupon 
Falsified Medicinal Products
UNODC 1
Member State Mechanism on Substandard and Falsified Medical 
Products
WHO 1
WHO Annual National Centres Meeting of Countries participating 
in the Programme for International Drug Monitoring (PIDM)
WHO 1
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